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5Abstract
Lyme disease is the most common human tick borne disease in the northern hemisphere, and 
the southern coastline of Norway is a high endemic region regarding Lyme disease.
European Lyme neuroborreliosis (LNB) often presents with a sub acute painful lymphocytic 
meningoradiculitis (Bannwarth syndrome) with or without paresis in the abdominal wall, the 
limbs or muscles innervated by cranial nerves. Central nervous system involvement as 
encephalitis, myelitis and vasculitis is rare.
Most LNB patients experience marked improvement in neurological symptoms within weeks 
to a few months after antibiotic treatment, but years after treatment 10 – 50% report persisting 
or new symptoms including fatigue, concentration difficulties and musculoskeletal problems.
Remaining complaints after adequately treated Bb infections are often named Post Lyme 
Disease Syndrome (PLDS). The prevalence and impact of PLDS is debated since similar 
symptoms are common in the general population, and there are few European controlled 
studies on the issue. Most studies on outcome after LNB are conducted in the US, and as 
Borrelia genotype and the clinical picture of Lyme disease in the US differ somewhat from 
what we find in Europe, the study results are not necessarily transferable to European patients.
Aims
Our aim was to assess the long-term impact of LNB on Health Related Quality of Life
(HRQoL) in a controlled study of well-characterized adult European LNB patients.
We also wanted to compare the neuropsychological (NP) functioning by assessing 
executive/attention functions, processing speed and memory in a group of adult LNB patients 
30 months after treatment to a matched control group. Finally, we wanted to identify clinical, 
demographical or laboratory factors associated with a reduced HRQoL and fatigue after 
treatment of LNB.
Patients and methods
A cohort of 50 patients was followed for 30 months after treatment for LNB. The patients 
were recruited from a treatment study conducted in southern Norway comparing per oral 
doxycycline to intravenous ceftriaxone. All patients were living in the geographical region of 
Agder Counties, and received treatment between May 2004 and December 2007.
The LNB patients brought a control person from the same geographical area, matched for age, 
gender and education level. Exclusion criterion for the controls was a history of 
acknowledged LNB. 
6At basis pre-treatment and at 4, 12 and 30 months we did a semi structured interview, a 
clinical score, and spinal and blood tap. At 30 months NP functioning was assessed, and all
participants completed the following questionnaires: the Fatigue Severity Scale (FSS), the 
Montgomery-Åsberg-Depression Rating Scale (MADRS), and the Short Form-36 (SF-36: A 
HRQoL questionnaire including the sum scores Mental Component Summary (MCS) and 
Physical Component Summary (PCS)). They were asked about previous and current 
coexisting diseases, psychological distress and subjective complaints. A composite clinical 
score made for the treatment study, summarizing subjective complaints and objective 
findings, was used to assess clinical status. Non-complete recovery was defined as more than 
1 point score on the composite clinical score.
The four NP tests in our test panel consisted of 23 subtasks, and we calculated a sumscore 
expressing tKHQXPEHURI13VXEWDVNVZLWKVFRUHV-1 SD from the mean in the control group 
(range 0-23). The sumscores were then categorized into three groups: Normal: 1--1 SD 
from the mean sumscore in the control group), deficit: 6-8 (>-1-6' from the mean 
sumscore in the control group) and impairment: 9-23 (>-2 SD from the mean sumscore in the 
control group). 
In the study regarding risk factors we did a univariate analysis comparing independent 
demographical, clinical and laboratory data to the PCS, MCS and FSS scores to look for 
associations. The variables which were associated with the outcome in the univariate analyses
were analyzed further in a multiple regression model.
Before treatment 80 % of the patients had a complete or partial Bannwart syndrome, and 8 % 
had symptoms suggesting involvement of the central nervous system (myelitis, ataxia and 
confusion). Fifty percent were treated with oral doxycycline and 50 % with IV ceftriaxone. 
Sixty-eight percent were classified as definite LNB according to the criteria of the European 
Foundation of Neurological Society, and 32 % as possible LNB. Mean age at follow up was 
55, and 58 % were male.
Results
Paper I: LNB treated patients had reduced HRQoL compared to controls as assessed with the 
SF-36 summary components PCS (P<0.001) and MCS ( p=0.010) 30 months after 
treatment. The patients scored lower on all the eight subscales of the SF-36, except for bodily 
pain. The LNB patients who reported complete recovery (56%) had similar HRQoL scores as 
the controls.
7Paper II: LNB treated patients scored lower on four NP subtasks assessing 
executive/attention functions, processing speed, visual and verbal memory, as compared to 
matched controls: Stroop test 4 (P=0.015), TMT 5 (P=0.004) Digit Symbol recall (P=0.038) 
and CVLT list B (P=0.003). The distribution of global NP function  indicates that most of the 
LNB treated patients perform comparable to controls, while a small subgroup have a 
debilitating long-term course with cognitive impairment. Fatigue, depression, neurological 
deficits or HRQoL at 30 months after treatment were not associated with the global NP sum 
score. Eighteen out of 50 patients (36%) had objective findings in terms of neurological 
deficits and/or cognitive impairment.
Paper III: Delayed start of treatment and remaining complaints 4 and 12 months after
treatment seem to predict a worse outcome with respect to HRQoL. Delayed start f treatment, 
a more severe disease pre-treatment and remaining complains at 4 and 12 months after 
treatment seem to predict more fatigue at 30 months. Age, gender, educational level, 
diagnostic accuracy, treatment option, signs of infection in the central nervous pre-treatment 
or coexisting somatic diseases or psychological distress were not associated with HRQoL 
outcome 30 months after treatment in our cohort,  neither were any of the assessed CSF 
findings before treatment or during follow-up .
Conclusions
1. HRQoL was reduced in well-characterized European patients treated for LNB with a 
current recommended antibiotic regimen 30 months earlier, as compared to matched controls. 
The LNB treated patients were not more depressed and did not report more pain than the 
controls. Fatigue was the most disturbing persisting complaint, and was negatively associated 
with HRQoL. Mild neurological deficits were found in 28 % of the patients, and seemed to 
influence negative on the physical HRQoL and fatigue scores. The patients who reported 
subjective recovery had the same HRQoL as the controls.
2. Most of the patients who were treated for European LNB 30 months earlier had comparable 
NP functioning to matched controls, but a small subgroup had cognitive impairments
regarding attention/ excecutive function, processing speed and memory that could affect their 
daily life. The LNB treated patients with complete recovery had similar NP functioning as the 
controls. We did not find any association between NP test results and HRQoL or fatigue.
3. It seems as a more serious LNB disease and a longer duration of symptoms before 
treatment can reduce HRQoL, and as symptom duration more than 6 weeks before treatment, 
8a more severe disease and non-complete recovery at four and 12 months predict a higher 
burden of fatigue 30 months after treatment. We did not find that any laboratory data 
predicted outcome after treated LNB,  or that any  CSF finding indicated an active Bb
infection 30 months after treatment. Gender, age, comorbidity, signs of pre-treatment 
infection of the central nervous system or CSF findings before and during follow-up were not 
associated with HRQoL or fatigue at 30 months.
4. Thirty months after treatment of LNB 18 out of 50 patients (36%) had objective findings in 
terms of neurological deficits and/or cognitive impairment.
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1. Background
1.1 Lyme disease.
1.1.1 The history and epidemiology of Lyme disease (LD)
The story of Lyme disease (LD), named from the region Lyme in Connecticut, is legendary. It 
shows us that important and unexpected solutions can often be founded upon the hard work of 
open-minded researchers who take the concerns of the public seriously. The descriptions of 
LD, the identifying of its vector; the hard shell tick Ixodes, and the discovery of the causative 
spirochete bacteria Borrelia burgdorferi (Bb), have occupied researchers all over the world 
for hundreds of years. The fact that ticks can cause diseases in humans has been known even 
from the antics and from the travel books of Dr. Livingston [1], and the most common clinical 
picture of disseminated disease in Europe, the Bannwart syndrome, was described by 
Bannwart in 1941 [2]. An important break-through came in the seventies when two observant
mothers reported joint swelling and the typical rash Erythema Migrans in several children in 
their neighborhood, and field researchers connected the symptoms to the ticks in the bushes 
along the riverbanks in Lyme [3]. In 1981 the spirochete Bb was discovered [4], and since 
then the research field of “Borreliology” has become an expanding but also a controversial 
arena. There are still many questions regarding LD symptoms, treatment and prognosis to be 
answered.
The Bb bacterium generates various clinical diseases in humans and animals. In the northern 
hemisphere LD is the most common vector borne disease. Surveillances from different 
regions show us that the incidence of Bb infections varies considerably. In Norway the trend 
has been that the incidence of disseminated LD has grown slowly, but in the last years it 
seems to have stabilized with about 300 reported cases annually. In the high endemic regions 
of Aust- and Vest-Agder counties the incidence rates are 29.8 and 36.9 per 100 000 
population respectively (numbers are from MSIS (MeldeSystemet for smittsomme 
(Infeksjons) Sykdommer) www.msis.no, Norwegian surveillance for infectious disease the 
Norwegian institute of Public Health). In the US the annual rate varies between 0.01 per 
100 000 population in low endemic states, to 73.6 per 100 000 population in Connecticut in a 
15 years period [5].
13
In general there has been a slightly growing prevalence of ticks, Bb and tick-borne diseases in 
the last decades. Farmland reverting to woodland, increasing number of deer and rodents, 
climate changes and bird immigration all contribute to this. Human behavior leading to the 
change of the landscape because of less agriculture in many countries is probably the main 
reasons for the increasing concentration of ticks and its parasites [6].
1.1.2 Borrelia burgdorferi (Bb) sensu lato and its vectors
The genus Borrelia consists of two major human pathogenic groups; Borrelia recurrentis, the 
agent of relapsing fever, and Borrelia burgdorferi (Bb) sensu lato group causing LD. New Bb 
species are discovered regularly, and there are regional differences in the distribution of ticks, 
hosts and Bb species. In Europe, at least five species of Bb sensu lato are pathogenic for 
humans, namely Bb sensu stricto, Bb garinii, Bb afzelii, Bb spielmanii and Borrelia
bavariensis [7]. In the US LD is almost exclusively caused by the genotype Bb sensu stricto.
In southern Norway, where this study was carried out, a study of prevalence and genotypes of 
Bb in ticks shows that we have mainly Bb afzelii (60%) and Bb garinii (23%), followed by 
Bb sensu stricto (11%) and Bb valaisiana (5%) [8].
A vector is an organism that carries a parasite or pathogen from host to host, and the gram
negative Bb bacterium is totally dependent of its vectors and hosts and cannot survive outside 
them. In US the most common vectors are the ticks Ixodes scapularis and Ixodes pacificus. In 
Europe the tick Ixodes ricinus is the preferred vector, although other vectors can be found. 
The ticks are mainly active during summer and autumn, but if the temperature is above 4-5
degrees Celsius, and the surroundings are not too dry, you can find active ticks around the
year along the southern coastline of Norway. The life cycle of the Bb typically lasts 2-3 years, 
and consists of three life stages, larva, nymph and adult. The primary Bb reservoir is mice and 
other small vertebras [5]. The ticks are inoculated with Bb when they feed blood, mainly from 
rodents and birds, and the ticks then transmit the Bb infection to other hosts like deer, or 
humans. The Ixodes ricinus needs two blood meals during one life cycle, and in addition the 
female tick needs a blood meal before she can produce eggs. Not all ticks are infected with 
Bb, and a recent study showed that the infection rate of the ticks in Agder counties was 22-
31% [8]. Interestingly, some host animals, like deer, have developed strategies that protect
them from infection with Bb, even if they are attractive hosts for ticks. Hunters in Norway tell 
stories about how they have found hundreds of ticks on one prey. The protection strategies are 
probably due to activation of the complement system in these animals [9]. The Ixodes ricinus
14
may also carry other much less frequent human pathogens such as Tick borne encephalitis
(TBE) virus, Anaplasma phagocytophilum and Babesia.
1.1.3 Clinical stages of Lyme disease
Persons who were frequently out-of-doors in a high endemic region regarding LD in Sweden 
had a risk of 4 % per 10 hours spent outside of getting bitten by a tick [10], and a Germany 
study found that 2.6 % of tick-bitten individuals will develop LD [11]. The risk of getting 
infected with Bb after a tick-bite depends on several factors: how many ticks a person gets 
bitten by, for how long the tick feeds, if the tick is Bb infected, and what species of Bb are 
transferred [12].
In Norway the most common presentation of disseminated disease is Lyme Neuroborreliosis 
(LNB) (70%), followed by arthritis (20%) and the chronic skin affection Acrodermatitis 
Chronica Atrophicans (ACA) (numbers taken from MSIS). Bb heart affection is feared 
because of the potential serious conduction defects. The condition it is rare in Norway, but 
case reports do exist [13].
A stage classification based on the clinical presentations of LD, from localized disease with 
the typical skin infection Erythema Migrans (stage I), through the early disseminated stage 
with organ manifestations (stage II) to the late disseminated disease with symptoms persisting 
for more than 6 months (stage III) is commonly used. Even if this is the most typical 
progression of LD, it is important to know that LD may present primarily in any of these 
stages (see Table 01). Subclinical and asymptomatic courses are usual, and studies of blood 
donors in the high endemic region of southern Norway have shown that as much as 15-20 % 
of the population is positive for anti-Bb antibodies in serum despite no clinical history of LD 
[14].
Table 01. Stages of Lyme disease (LD). LD can present primarily in any of these stages, does 
not always progress from one stage to another, and can also have an asymptomatic course.
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Localized disease LD 1-21 days after 
tick bite
Erythema migrans
Lymfocytoma
Early disseminated LD Starts 6-8
weeks after tick 
bite
Neuroborreliosis (LNB)
Arthritis
Carditis with conduction defects
Other organ manifestations 
Late disseminated LD > 6 months after 
tick bite
Acrodermatitis Chronica Atroficans (ACA)
Chronic arthritis
Late neuroborreliosis
Post Lyme Disease Syndrome 
(PLDS)
Months to 
years after tick 
bite
Musculoskeletal  pain
Cognitive problems
Fatigue
Localized disease, stage I: Erythema Migrans, the most characteristic skin manifestation (but 
not the only possible rash) is a slowly annular spreading rash around the site of the tick-bite 2-
30 days after a person has been bitten. It can be accompanied by nonspecific “flu like” 
symptoms. At this stage the diagnosis is based on the history of tick-bite and clinical 
observations. Laboratory tests are seldom supportive of the diagnosis in stage I, and are not 
recommended. The Erythema Migrans normally resolves spontaneously after a few weeks and 
the chance of dissemination is considerably reduced if the patient is treated with antibiotics at 
this stage [15]. Another more rare manifestation is the Borrelia Lymphocytoma, a mass of 
lymphocytes in the skin, characteristically located on the ear or breast, and mainly found in 
children.
Early dissemination, stage II: In 10 % of the untreated infected patients, the infection spread 
to other organs of the body and musculoskeletal, neurologic and cardiovascular symptoms 
may occur a few weeks to six months after the tick-bite [5]. Only half of the persons 
developing LNB remember a tick-bite, and even fewer remember an Erythema Migrans 
(30%) [16].
Late dissemination stage III:  If the infection last for more than 6 months, it is called late 
disseminated Lyme. The typical presentation of late dissemination in Europe is the chronic 
skin lesion ACA, sometimes with polyneuropathy [14]. Chronic arthritis, especially in the 
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larger joints (monoarthritis in the knee) and chronically progressive encephalomyelitis are 
rare manifestations [17].
Although most of the patients are diagnosed with LNB in the first weeks and months after the 
tick bite, up to 5 % get their first symptoms more than 6 months after the tick bite [18].
Post Lyme Disease Syndrome (PLDS): Wormser et al. have proposed a definition for PLDS. 
In short:  Persisting subjective symptoms like cognitive complaints, fatigue, or widespread 
musculoskeletal pain starting within 6 months after completed treatment with a generally 
accepted antibiotic regime for a documented episode of Lyme disease fulfilling the definition 
given by the Centre of Disease Control and Prevention (CDCP) [19].  The symptoms should
not be explained by any other condition, and they should be of such a severity that they 
reduce previous levels of everyday activities [20].
The term Chronic Lyme has been used to describe both symptoms and complaints in the late 
stage of the disease, and persisting complaints after treatment without any remaining signs of 
infection. In general, the neurological findings and symptoms in the early and late phase of 
the disease are successfully treated with antibiotics, and the infection is eradicated [21].
Researchers in the field borreliology have proposed diagnostic categories for persons who 
have symptoms attributed to “chronic Lyme disease” [22].
Only patients with category 4 disease have Post–Lyme Disease Syndrome (PLDS)(Feder et al.
NEngl J Med 2007) [22]
Studies from Lyme referral centers in the US show that only one quarter to one third of the 
patients seeking guidance about suspected “chronic LD” has or have ever had LD [23]. A
recent study from Germany highlights the importance of proper diagnostic workup in the 
group with suspected “chronic LD”. Out of 122 persons referred to a specialist center because 
Table 02 The four predominant categories of diseases associated with chronic Lyme disease.
Category 1 Category 2 Category 3 Category 4
Symptoms of unknown
cause, with no evidence
of Borrelia burgdorferi
infection
A well-defined illness
unrelated to B. 
burgdorferi
infection
Symptoms of unknown
cause, with antibodies
against B. burgdorferi but
no history of objective
clinical findings that are
consistent with Lyme 
disease
Post–Lyme Disease 
Syndrome (PLSD)
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a “chronic LD” condition was suspected, 7% were diagnosed with acute LNB and 50% had 
other diseases that explained their complaints, among them 13 patients with findings 
suggestive of Multiple Sclerosis. Six out of the 122 referred persons were diagnosed with a 
Post Lyme Disease Syndrome (PLDS) [24].
To avoid misunderstandings, in our opinion, the term ”chronic Lyme” is ambiguous and 
should not be used.  
1.1.4 Definition and clinical presentation of Lyme neuroborreliosis
In 2010 the European Federation of Neurological Societies (EFNS) reviewed the European 
guidelines on diagnosis and management of Lyme Neuroborreliosis, and suggested case 
definitions of definite and possible LNB [25].
Table 03 Suggested case definitions for Lyme Neuroborreliosis (LNB).
(Mygland et al. EFNS guidelines on the diagnosis and management of European Lyme 
Neuroborreliosis. Euro J Neurol 2010) [25]
a These criteria apply to all subclasses of LNB except for late LNB with polyneuropathy 
where the following should be fulfilled for definite diagnosis: (I) peripheral neuropathy (II) 
acrodermatitis chronica atrophicans (III) Bb-specific antibodies in serum.
b If criteria III is lacking; after a duration of 6 weeks, there have to be found Bb-specific IgG 
antibodies in the serum.
In most European countries, as reflected in the EFNS guidelines above, the detection of 
intrathecal production of anti-Bb antibodies is necessary to diagnose definite LNB. In the US 
this is not mandatory [26].
Another useful definition included in the EFNS guidelines is the distinction between early and 
late LNB [25].
Definite neuroborreliosis a
All three criteria fulfilled
Possible neuroborreliosis b
Two criteria fulfilled
1.Neurological symptoms suggestive of 
LNB without other obvious reasons
2.Cerebrospinal fluid pleocytosis
3.Intrathecal Bb antibody production
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Table 04 Classification of Lyme neuroborreliosis (LNB)
(EFNS guidelines of diagnostics and management of European Lyme neuroborreliosis Euro J 
Neurol 2010) [25]
Early LNB
Neurological symptoms for <6 months
With manifestations confined to the peripheral nervous system (cranial nerves, spinal roots
or peripheral nerves) (Bannwarth syndrome)
With central nervous system manifestations
Late LNB
Neurological symptoms for more than 6 months
With peripheral nervous system manifestations
With central nervous system manifestations
Early LNB:
In Europe, the most common clinical presentation of an infection of LNB is the Bannwart 
syndrome, with painful radiculitis and lymphocytic meningitis [2]. The pain is often described 
as waning and waxing, radiating and severe, especially at night [27]. Paresis of muscles in the 
limbs, the abdominal wall, or in muscles innervated by cranial nerves, most commonly the 
facial nerve followed by abducens and oculomotor nerves, occur frequently in Europe [28].
Stiff neck and headache are sometimes present. LNB may also rarely present as peripheral 
mononeuritis multiplex or plexus neuritis. Involvement of the central nervous system (CNS)
parenchyma is uncommon, but symptoms of myelitis and encephalitis as confusion, epileptic 
seizures, ataxia or tremor do occur [25].
Late LNB:
If untreated symptoms persist for more than 6 months, it is called late LNB. This can present 
as a progressive segmental myelitis, encephalitis or cerebral vasculitis, and cause symptoms 
like gait or bladder problems, spasticity or encephalopathy [29]. Mononeuropathy,
radiculopathy and polyneuropathy may also occur. Distal symmetric polyneuropathy is rarely 
seen in Europe in Bb infections, but polyneuropathy may occur in connection with ACA [14].
1.1.5 Patophysiology of Lyme disease and Lyme neuroborreliosis
Bb lives in the mid-gut of the hard shell tick, attached to the tick-gut epithelial cells by the 
outer surface protein Osp A. When the tick bites into the host’s skin the blood from the host 
flows into the tick gut and Bb is presented to the host’s blood. During the first 24-48 hours of 
tick feeding, Bb multiplies and prepares itself for the meeting with the immune system of the 
host. Then Bb migrates to the salivary glands of the tick and is transmitted to the host through 
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the tick salvia. It normally takes time before Bb is transmitted to the host, and if the tick is 
removed within 24 hours, the risk of an infection with Bb is considerably reduced [30;31].
Rupprecht has made a figure describing which mechanisms Bb uses to evade the hosts 
immune system (see figure 01) [32].
Figure 01. Mechanisms for Borrelia burgdorferi to evade the hosts immune system.
(Rupprecht et al. The Pathogenesis of Lyme Neuroborreliosis: From Infection to 
Inflammation. Mol med 2008, with permission) [32]
In humans Bb is attacked by the hostile immune system in several ways:  Bb surface proteins 
are recognized by the CD14 and the toll like receptor 2 (TLR2) of the innate immune system. 
Bb is confronted with the hosts complement system. Antibodies against Bb outer surface
proteins are produced by the activation of the acquired immune system. An important Bb
defense mechanism against attacks from the hostile immune system is a change of the surface 
molecules on the bacteria`s outer membrane, so called antigenic variation. The most 
important switch is probably between the very immunogenic outer surface protein Osp A to 
Osp C. Osp C attaches to a tick salivary protein which prevent activation of the host`s 
complement system and builds immune complexes with the anti-Bb antibodies. Bb also hides 
in less accessible compartments to the immune system like the extracellular matrix [32].
If the infection is established in the skin the rash develops annularly around the site of the 
tick bite. At this time the antibody production has normally not started, and the diagnosis is 
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clinical. The infection might remain localized, or disseminate to other organs like the heart, 
eye, joints, the peripheral or central nervous system. If Bb disseminates into the nervous 
system by the blood stream or along other structures like the peripheral nerves is not known.
It is possible that different species use different routes of dissemination, and that this 
phenomenon may be one of the reasons why the human clinical phenotype of LNB differs in 
different populations and geographical locations. The meningoradiculitis caused by the Bb
garinii is often localized near the primary site of infection and might have spread along the 
nerve fibers to the dorsal roots. The multiple Erythema Migrans and the more diffuse 
meningitis seen in humans in the US where the Bb sensu stricto is the only known causative 
agent of LNB, point to a more hematogenous spread of Bb [32].
The cause of the injury to the nervous system is unknown [33]. Bb is difficult to find in 
human tissue, and to learn more about the pathogenesis there is a need of good animal 
models. The only successful induction of reliable clinically manifest LNB in an animal model 
is in the immunosupressed monkey rhesus Macaque [34]. Cadavid et al. found spirochetes in 
the leptomeningies, the nerve roots and dorsal root ganglia of the ape, but the CNS 
parenchyma was not affected. This seems to be in accordance with the clinical picture of 
meningoradiculitis.
Research has shown that the different Bb species have various affinities to different human
tissue [35]. Bb sensu stricto is associated to arthritis, Bb garinii to LNB and Bb afzelii to 
dermatoborreliosis [36].
The ability of the Bb to survive in the host despite an intensive inflammation is a frequent 
cause of discussions, however, Bb is very susceptible to antibiotics like doxycycline, 
penicillin and ceftriaxone, and the main opinion is that when treated with adequate antibiotics, 
the Bb does not survive, and the infection is eradicated. 
1.1.6 Laboratory diagnosis of Lyme neuroborreliosis
The gold standard of laboratory diagnostics in infectious diseases, namely direct detection of 
the bacteria by cultivation or PCR has low sensitivity in LNB. The sensitivity of cultivation is 
10–30% in CSF in early LNB and less than 10% in blood of patients with an Erythema 
Migrans [37]. In Europe the PCR sensitivity is 23% in the CSF and 10% in the blood of LD
patients (% is mean of several studies in Erythema migrans and early disseminated LD)[38] .
Clinicians and researchers therefore have to depend on indirect laboratory methods. Most of 
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the time the diagnostic process is unproblematic if we evaluate clinical, anamnestic and 
laboratory findings together. Signs of inflammation are almost always present in the CSF in 
terms of elevated cell count to 10-1000 leucocytes / mm3, moderately elevated protein and 
CSF oligoclonal bands [39].
The anti-Bb-specific antibodies in serum and in CSF can be detected with an IgG- and IgM-
differentiating enzyme-linked immunosorbent assay (ELISA). Diagnostic sensitivity of 
ELISA screening assays in early LNB is 70–90%, and 90-100% in late LNB [25]. Some 
laboratories confirm the positive test with an immune blot with a higher specificity.
There are several pitfalls when considering the anti-Bb antibody findings: 
False positive IgM and IgG antibodies: The finding of anti-Bb IgM antibodies in serum 
without anti-Bb IgG antibodies must be interpreted with care as this can be result of cross-
reactivity or a non-specific response to another disease [40]. Anti-Bb IgG antibodies can be 
present in serum and CSF years after symptomatic and asymptomatic Bb infections, also at 
high levels, and it is problematic to use anti-Bb antibodies as a marker for successful 
treatment because of this [41].
False negative IgM and IgG antibodies: It might take several weeks to produce detectable 
levels of anti-Bb antibodies, so it is possible to have an active LNB without anti-Bb
antibodies. Later, within 6-8 weeks, anti-Bb antibodies are detected in almost 100 % of the 
LNB cases [42].
It is possible to have anti-Bb antibodies in CSF even if no antibodies are found in serum. This, 
combined with the fact that the clinical picture can be unclear, makes it necessary to do a 
lumbar puncture to look for inflammatory markers to diagnose a definite LNB [43].
Antibodies may leak from serum to CSF, and to prove that anti-Bb antibodies detected in CSF 
really are produced intrathecally, an antibody index is calculated which compares the 
antibody concentrations between the CSF and serum. A test like IDEIA Lyme 
Neuroborreliosis kit (DakoCytomation, Cambridgeshire, UK) corrects for the impairment of 
blood brain barrier. The antibody Index is calculated like this: (OD is optic density) OD CSF 
/OD serum x (OD CSF –OD serum [44].
The chemokine CXCL-13, a chemoattractant cytokine that attracts the B-lymphocytes to the 
site of the inflammation, has been extensively investigated during the last years, and seems to 
be useful in the early detection of LNB [45]. Detection of CSF CXCL-13  have a diagnostic 
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sensitivity of 100%  in the early phase of LNB,  as compared to a diagnostic sensitivity of  
89% of a positive Bb antibody index in a study of Ljøstad et al [46].
The potential failure of making a positive diagnosis due to  the insufficient tests available has 
led to a controversial marked for LNB testing, where many of the tests are used for diagnostic 
purposes before they have been properly evaluated. A critical evaluation of the available tests 
and recommendation of use are given in the EFNS guidelines. Currently the tests based on 
detection of antibodies are the most reliable and the ones recommended [25].
The use of imaging procedures as diagnostic tools, such as MRI, has not been very helpful 
until now [47]. If the clinical manifestation and the anamnesis points towards a diagnosis of 
LNB, a contrast MRI imaging technique that shows signs of nerve root and meningeal 
enhancement can support the diagnosis of LNB [48]. MRI of patients with acute LNB and 
encephalopathy might show white matter lesions [49]. The general lack of findings in 
structural imaging is in accordance with the fact that the Bb seldom affects the parenchyma of
the CNS. Functional imaging techniques such as Single Photon Emission Computed 
Tomography (SPECT) have demonstrated abnormalities suggestive of reduced blood flow 
and metabolism [50;51]. More functional studies are necessary, not least because LNB patents 
with persisting complaints report functional problems like cognitive difficulties and fatigue. 
1.1.7 Prevention and treatment of Lyme disease and Lyme neuroborreliosis
Avoiding known tick-infested areas may of course prevent LD, but this is a bit dramatic, and 
even though the chance of getting a tick bite is considerable in certain areas, the risk of 
serious disease is low. To prevent tick bites it is recommended to use insect repellant and 
wear long pants tucked into boots and long sleeves to protect the skin. Skin, clothing and pets 
should be examined for ticks, and ticks must be removed immediately with fingernails or with 
tweezers. A single dose of Doxycycline after the bite might prevent disease, but is not 
recommended because of the low chance of being infected combined with ecological and 
other considerations [52]. At the present time there are no available vaccines against infection 
of Bb.
The EFNS guidelines suggest treatment for14 days with per oral doxycycline (or penicillin) 
for LNB unless CNS involvement is suspected, in which case intravenous ceftriaxone for 14 
days is recommended [25]. A non-inferiority study of the two treatment options in 112 
unselected LNB patients with all stages and clinical manifestations has shown that the two 
treatment options are equally effective [39].
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1.2 Prognosis after treated Lyme Neuroborreliosis
Most  LNB patients who receive current recommended antibiotic treatment regimens have a 
decline in their CSF cell count and experience a marked relief of subjective symptoms and  
regression of objective neurological deficits within weeks to a few months after treatment, 
sometimes even after just a couple of days [39]. Despite this, up to 50% of the treated LNB 
patients complain about persisting symptoms. The most common post-LD complaints are 
arthralgia, fatigue, reduced quality of life and neurocognitive problems in addition to mild 
neurologic findings [52-55].
1.2.1 Health Related Quality of Life 
The World Health Organization (WHO) defined quality of life as “an individual’s perception 
of his or hers position in life in the context of the culture and value system in which he or she 
lives and in relation to his or hers goals, expectations, standards and concerns”. It is a broad-
ranging concept affected in a complex way by the person’s physical health, psychological 
state, level of independence, social relationship, and relationship to salient features of the 
environment [56].
The term “quality of life” is incorporated into everyday vocabulary, but the concept of quality 
of life is not definitely defined. It has gradually come to mean subjectively assessed 
dimensions of life, mostly including physical and social functioning, emotional or mental 
state, tiredness, pain and sense of well being [57]. The concept of quality of life has different 
meanings within various fields. In a medical context we use the term “Health Related Quality 
of Life” (HRQoL), referring to how a person’s wellbeing may be affected by a disease. A 
person diagnosed with a serious disease does not necessarily have a poor HRQoL, and the
other way around, a person who have few objective signs of his or hers disease might have a 
poor HRQoL.
The need of standardized measurement of the patient’s distress and functional impairment has 
increased. In the past, when most diseases were acute and life-threatening infectious diseases, 
the impact of medical care could be evaluated by mortality. Today the chronic diseases are 
more common, especially in the developed countries. The patient’s subjective health 
perspective has become increasingly accepted as central to the monitoring and evaluation of 
medical care. The assessment of the relative improvement of a patient’s condition is also 
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important when new medical care (like a new drug) is implemented. HRQoL measurements 
are regularly used to evaluate the benefit of new treatments and managements in cost-benefit 
analyses. 
In clinical studies it is increasingly common to include a standardized questionnaire of 
HRQoL as one of the outcomes. This can contribute to uncover negative effects on a person’s 
quality of life that more traditional measures as clinical, radiological and laboratory outcome 
measures might have missed [58].
HRQoL assessments can be used to compare groups and for longitudinal observations of 
populations. In populations with neurological diseases evaluation of a patient’s quality of life 
is very useful. Neurological diseases are regularly chronic and incurable, and functional 
problems induced by the cerebral pathology that can affect daily life are common. 
The most frequently reported complaints after LNB are pain, fatigue and cognitive problems. 
These symptoms are subjective and unspecific and in addition common in the general public. 
None of these complaints are easily evaluated, but they may all have an impact on HRQoL. 
Mental and physical problems including fatigue are known to influence Quality of Life[59].
1.2.2 Assessment of Health Related Quality of Life
There are several methods to measure quality of life, and the ideal method of assessing this 
subjective phenomenon does not exist. Some of the methods are disease specific or focus on 
special patient groups or areas of function, but most of them are generic, designed to be 
relevant to a wide range of health problems and to the general population. If a more global 
evaluation of HRQoL is warranted, a generic instrument that can be applied independently of 
diagnosis is recommendable. This can be used to compare a group of patients to healthy 
controls, to a control group with another disease or to the general population [60]. Generic 
instruments will be less specific to the actual disease, though.
To choose the right instrument for assessing HRQoL, reliability (reproducible and consistent 
results) and validity (the test measures what it intends to measure) are the most important 
factors. The instrument must be sensitive (detect real differences) and the scale must be 
responsive (able to detect changes). It is also important that validated translated versions in 
the language of the population of interest are available, and if possible, national normative 
data. 
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The use of self-administered questionnaires for assessment of HRQoL is less time consuming 
and cheaper than investigator-administered questionnaires.
Most HRQoL questionnaires are multi-item dimensions which assesses subjective experiences 
and functional status including at least physical, psychological and social factors. These 
dimensions can be used to evaluate different elements of quality of life, and to make a 
HRQoL profile in a person or a group. Because we often want to consider a global health 
outcome, sum components are often calculated based on the different dimensions. A typical 
example is the Physical Component Summary (PCS) and the Mental Component Summary 
(MCS) of the HRQoL questionnaire Short Form -36 (SF-36).
The assessed HRQoL change over time or difference between groups must be both 
statistically and clinically significant and reflect real changes that are of importance in a 
person’s daily life. The results of previously conducted studies and experience from clinical 
praxis will help us to decide what differences are clinical meaningful to detect.
The impact of a person’s reduced HRQoL on his or hers daily living is a matter of individual 
consideration, and many questionnaires also aim to evaluate this aspect by asking specifically 
how complaints like pain or fatigue influence the ability to do tasks, e.g. walking up steps. 
The subjective feeling of HRQoL can also change over time, and most questionnaires are 
restricted to a period of time. The SF-36 version 2 (that we used in our study), asks questions 
about the feelings and experiences the last four weeks. (For more detailed description of SF-
36 see in method part of thesis).
1.2.3 Studies of Health Related Quality of Life after Lyme disease and Lyme 
neuroborreliosis
Several US studies on outcome after Lyme disease have included a HRQoL questionnaire in 
their evaluations, the most commonly used being the SF-36. The most important studies are 
listed in Table 05. 
Table 05. Studies of Health Related Quality of Life (HRQoL) in Lyme Disease (LD) patients 
using Short Form -36
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Studies Material Design HRQoL results
[61] Shadick et al. 1994
Ipswich, Massachusetts, 
USA
38 LD patients  6.2 years after 
treatment
43 Healthy controls
Retrospective cohort 
study
Poorer global health 
status in treated LD 
patients
[62] Shadick et al. 1999
Nantucket Island, 
Massachusetts, USA
186 LD patients 6 years after 
treatment
167 controls
Retrospective cohort 
study
Lower scores in all 8 but 
energy dimension in 
treated LD patients, only 
bodily pain significant in 
final model. Physical 
dimensions were worse
[63] Kalish et al. 2001
Lyme, Connecticut, USA
Facial Palsy (31, treated 15)
Erythema Migrans (25)
Lyme Arthritis (28)
Control Subjects (30)
Follow-up study of  the 
Lyme population
Lower scores in body 
pain and physical
limitations dimensions 
were found in some 
patients with untreated  
LD facial palsy 
[64] Klempner et al. 2001 
Boston, USA
78 seropositive LD patients 
with persistent symptoms
51 seronegative  LD patients 
with persistent symptoms
Placebo controlled 
treatment trial
Impairment of HRQoL 
in all LD patients, no 
improvement with 
second  antibiotic course 
[65] Seltzer et al. 2000 
Connecticut , USA
88  LD patients
88 controls 
Cohort study, matched No significant difference 
in HRQoL between 
controls and LD patients
[66] Krupp et al. 2003
Long Island, USA
28 patients with treated LD 
and fatigue
27 controls treated LD
Controlled treatment 
trial                
Ceftriaxone 28 days/ 
placebo
No significant 
improvement in HRQoL 
in LD patients after 
treatment
[67] Fallon et al. 2008
New York, USA
37 PLDS patients
20 PLDS controls 
Double blind, placebo 
controlled treatment 
trial 
Ceftriaxone/placebo
Improvement  of 
Physical Component 
Summary in  ceftriaxone 
treated PLDS patient 
group, more 
improvement if severe 
disease 
[68] Kowalski et al. 2011
USA
15 LD facial palsy patients
3 LD patients with localized 
disease
4.6 years after treatment
Retrospective double 
cohort study
Social function 
dimension scores were 
lower in LD facial palsy 
patient group.
In 2010 Kowalski et al. (USA) did a retrospective study and found that persons with longer 
duration of antibiotic treatment scored lower on the dimension social functioning of the SF-
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35. They did not find differences in HRQoL between persons with definite or possible LD 
[69].
The US studies vary in design and inclusion criteria, making direct comparison of the studies 
difficult. Because of different Bb, the situation of the PLDS group regarding HRQoL might be 
different in Europe. We have not found European HRQoL studies of treated LNB patient 
which include a control group. 
1.2.4 Fatigue
Definition
Fatigue can be described as a subjective overwhelming sense of tiredness, lack of energy or 
feeling of exhaustion [70]. Another definition is a subjective lack of physical and/ or mental 
energy that is perceived by the individual or caregiver, and pronounced enough to interfere 
with usual or desired activities [71]. Fatigue is distinct from limb weakness. It is not the same 
as sleepiness, and sleep does not give satisfactory relief of the symptoms. Fatigue is common 
in depression, and the symptoms of fatigue overlap with the symptoms of depression. The 
symptoms of low self-esteem, despair and feelings of hopelessness are more prominent in 
depressed than fatigued persons and this can be used to distinguish between these two 
conditions [72]. Fatigue and apathy are often confused with each other. Apathy is defined as a 
disorder of motivation with diminished goal directed behavior and cognition. In many 
neurological diseases, as Parkinson, both apathy and fatigue are frequent, often co-existing 
[73]. In studies regarding fatigue, both the assessment of depression and apathy should be 
considered. 
Epidemiology
Fatigue is common in the general public [74] and in a Norwegian survey, 11.4% of the 
population reported chronic fatigue [75]. In a surveillance from 2005 using the Fatigue 
Severity Scale (FSS) it was found that 47 % of the Norwegian population was fatigued if they 
applied the recommended cut-off for significant fatigue of FSS  [76]! If FSS ZDVXVHG
as cut-off, however, the fatigue burden in Norwegians was 23 %, comparable to populations 
in other countries. 
In clinical praxis physicians regularly meet patients complaining of fatigue. It is well known 
that many physical and mental conditions are complicated by fatigue, like hypothyroidism, 
anemia, cancer, neurological diseases, systemic diseases and psychiatric diseases [77;78].
Fatigue is also common as an adverse effect of medical treatment. 
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Fatigue in neurological diseases
In many neurological diseases fatigue is chronic and fluctuates in intensity, reduces quality of 
life and affects negatively social and occupational activities. Fatigue in Multiple Sclerosis 
(MS) patients is a classic example, and most of the fatigue related research is done on the MS 
population. Eighty to ninety per cent of patients with MS report fatigue [79]. The burden of 
fatigue is the most disturbing symptom for many MS patients, and may occur even if they 
have little or no physical problems related to the disease. Fatigue is one of the main reasons 
why many MS patients don’t work [80].
Post-infectious fatigue 
Post-infectious fatigue is also common. A prospective cohort study from 2006 conducted in a 
rural area in Australia found that a minority (12% of 253 patients at 6 months) of patients got 
a relatively uniform post- infective fatigue syndrome consisting of musculoskeletal pain, 
neurocognitive difficulties, mood disturbances and disabling fatigue after even the most 
common viral infections, and the condition might persist for 6 months and more. The most 
important predictive factor of this syndrome was a more severe illness. Demographic, 
psychological or microbiological factors did not predict fatigue in this cohort [81].
For many years now, patients have been diagnosed with Chronic Fatigue Syndrome (also 
called Myalgic Encephalomyelitis), a condition with unknown pathogenesis and etiology. No 
psychological or somatic explanation has been found. This syndrome, with an incidence of 
0,2 to 2.6% [82], and with a number of changing definitions [83], has overlapping 
symptomatology with many other unexplained clinical conditions like fibromyalgia, the 
irritable bowel syndrome and multiple chemical sensitivity [84]. Studies of fatigue have 
shown that fatigue is an important factor in acute LD and in PLDS (see table 06). Subjects 
with anti-Bb antibodies report more fatigue than seronegative subjects [85]. There have been 
vivid discussions about LD and its role in the development of Chronic Fatigue Syndrome and 
”chronic LD” has been associated with the "medically unexplained symptoms" syndromes. A
similarity between these conditions is that we do not know the pathophysiology causing the 
fatigue, and there is no cure. The chronic fatigued patients with ill defined conditions like 
Chronic Fatigue Syndrome feel even more insecure, confused and abandoned by the health 
care system [86]. A very interesting study found differences in the proteome profile in these 
Chronic Fatigue and PLDS [87].
Pathogenesis
The pathogenesis of fatigue is unknown, and many theories have been discussed during the 
last 20 years. The origin of fatigue is probably not connected to a specific anatomical region 
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in the brain and certainly not to one medical condition. The discussion of released 
inflammatory cytokines that starts tissue damage or change the pathways and balance of 
hormones and transmission substances are very interesting. In MS, often used as a model 
disease to illustrate different theories about fatigue, the role of the corticotrophin hormones 
are of special interest. Cortisones play an important role in the treatment of relapses in MS, 
and MS patients often describe an increased energy level during the cortisone cure. It is also 
proposed that changes in the metabolism in the frontal cortex or basal ganglia can cause 
fatigue [88].
Treatment
Secondary causes of fatigue like depression, poor sleep, pain, medications and deconditioning 
are probably the first issues to address [88]. Non-pharmacological approaches like exercise 
and cognitive behavioral therapy have shown to be effective treatment options in fatigued 
persons [89]. In MS pharmacological therapies like Amantadine, Pemoline and Modafinil 
have been tried out, but with questionable effect [88].
1.2.5 Assessment of fatigue
Fatigue is a subjective symptom, and difficult to measure. There are numerous assessment 
tools on the marked, but only two fatigue self-rating questionnaires are translated into 
Norwegian; the Fatigue Questionnaire (FQ) and the Fatigue Severity Scale (FSS). Both are 
validated in the Norwegian general population and are generic. Fatigue Severity Scale (FSS) 
is widely used, validated and reliable, and has main emphasize on physical fatigue and its 
impact on daily living. It is also used in several outcome studies after treated LD (see Table 
06). A more detailed description of the FSS is to be found in the method section of this thesis.
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1.2.6 Studies of fatigue in Lyme disease and Lyme neuroborreliosis
Table 06. Studies of fatigue in Lyme Disease (LD), Lyme neuroborreliosis (LNB) and Post 
Lyme Disease Syndrome (PLDS) using Fatigue Severity Scale (FSS)
Study Material Design Results
[90] Krupp  et al. 
1991
New York, USA
15 LNB patients with 
memory disturbances 
6.7 months after 
treatment 
10 controls
Retrospective, 
matched controls
Fatigue correlated with memory
deficiencies
[91] Bujak et al. 
1996
USA
23 LNB 5.6 years after 
treatment
23 Recovered  LD 
patients
Retrospective,  
matched controls
Fatigue in initial phase prognostic 
factor for  poorer NP performance later
[92] Ravdin et al. 
1996
USA
21 LD patients
21 Osteomyelitis
21 Healthy control 
Prospective
Controlled
Fatigue worse in LD patients, inverse 
correlated with memory deficiencies
[93] Gaudino et al. 
1997
USA
38 LNB patients with 
fatigue                       
25 Chronic Fatigue 
Syndrome                
56 Healthy controls
Retrospective 
Controlled
High incidence of fatigue  in treated 
LNB and Chronic Fatigue Syndrome 
patients
[94] Pollina et al. 
1999
USA
16  LD treated patients 
with persistent 
complains                  
15 Healthy controls
Retrospective
Controlled
More fatigue in LD treated patients, 
but no  impact on NP performance 
[66] Krupp et al. 
2003
USA
28  LD treated patients 
ZLWKIDWLJXH)66
score) 
27 LD patients 
controls
Randomized 
Controlled 
treatment trial 
Ceftriaxone 28 
days/placebo
FSS score reduced with more than 0.7 
points in 69% of LD patients vs. 23 % 
in placebo group 
[67] Fallon et al. 
2008                 
New York, USA
23 PLDS patients  
Antibiotics
37 PLDS patients 
Placebo
Double blind, 
placebo 
controlled 
treatment trial
Improvement fatigue at 12 weeks in 
treated group, not at 24 weeks. Post-
hock analysis found the same as Krupp 
(68% reduction 0,7 points on FSS 
scale vs. 25%  placebo)
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Based on these studies it is reasonable to conclude that fatigue is well known in LD and LNB 
treated patients, also years after treatment. The patophysiology is unknown, and repeated 
antibiotic cures have not shown convincing efficacy in reducing fatigue over time. 
1.2.7 Cognitive problems and assessment of neuropsychological function
The science of neuropsychology aims to identify and quantify the cognitive consequences of 
brain injury. The definition of cognition varies throughout the literature. In general cognition 
is often assessed by Intelligence Quotient (IQ) tests presumed to reflect general cognitive 
ability. IQ refers to a derived score often included in Neuropsychological (NP) assessments. 
The NP tests assess NP functions like attention/executive functions, language, memory and 
visual motor skills. NP might help to detect more subtle problems and deficits in connection 
with diseases that affect the central nervous system. The knowledge of a person’s cognitive 
abilities, deficits and impairments can help us to understand the complexity of the burden of 
disease, and to plan treatment strategies and interventions based on strengths and weaknesses 
based on the individual cognitive profile. Poorer test results in a group or on an individual 
level do not always implicate clinical consequences as this is highly dependent on the 
demands of the individual in everyday life and a person’s ability to compensate.
The NP tests are often multifactorial, and the test results often rely on several functions, not
only the single function it is primarily designed to measure. For example, one commonly used 
test, the Trail Making Test (TMT), where the participant has to draw lines to connect letters 
and numbers depend on motor skills, attention, executive functions and processing speed. The 
NP tests are sensitive but have a low specificity and assess cognitive functions with a great 
deal of overlapping. The different cognitive domains are also highly dependent on each other, 
an example is the executive functions that are highly dependent on attention, and it is 
therefore common to assess and analyze these aspects of cognition together [95].
The decision of what NP test to use can be difficult. There are many tests and test batteries 
available. Another challenge for Norwegian researchers is that few NP tests have been 
standardized nationally. In some tests as the Delis-Kaplan Executive Function System (D-
KEFS) and the California Verbal Learning Test (CVLT) the original norms have been tried on 
a limited sample of Norwegians and found to be applicable [96;97].
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Studies that apply NP assessments are not always easy to compare to each other because of 
the different tests used and the possibility of different interpretations of the test results. Many 
factors can influence the test results, like age, educational level, coexisting diseases, 
psychological conditions and test situations. The scores obtained from the individual tests 
have to be compared to a control group or normative data from the general population, mostly 
stratified by age.
The tests are usually administrated in a defined way in formal environments by a trained 
neuropsychologist. The Norwegian NP Commission recommends that a non-
neuropsychologist who is going perform the NP tests has to go through training guided by an
experienced neuropsychologist, and has to read the guidelines for NP testing given by the 
International Test Commission. 
Tests assessing the functional areas of IQ, attention, executive functions , language, memory 
and visual motor skills are often included in a comprehensive NP assessment, but based on 
what information is considered most important in the given situation, focus may be restricted 
to only one or a few of these domains. Studies of neurocognitive functions often include an IQ 
test (most commonly a WAIS tests) or estimation of IQ and an evaluation of the premorbid 
functioning. 
Attention/executive function 
Attention/executive functions refer to higher order cognitive functions that are important to 
control and regulate goal directed behavior. Deficits in attention/executive functions may lead 
to problems in planning and initiation of activities, in interaction with other individuals and in
the control of emotions and impulses. Attention/executive function problems are typical of 
brain injuries in the frontal lobes and/or its white matter pathways [95].
Executive functions are highly dependent on attention, and therefore these two aspects of 
cognition are often assessed and analyzed together.
The Stroop test and the TMT test are typical tests for assessing attention/executive functions, 
and the color-word interference, an adapted version of Stroop, and the TMT1-5 is translated 
into Norwegian as part of the D-KEFS test battery. Out of practical reasons the word-color 
interference test is called the Stroop-test in this thesis. 
Processing speed
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The term “processing speed” covers reaction time and perceptual-motor speed and deficits 
may be seen as cognitive slowing. Motor deficits in e.g. the hand reduce the fine motor speed, 
and can reduce processing speed even if there are no cognitive deficits. This must be kept in 
mind when using tests that requires drawing/ writing, like TMT and Digit symbol test. This 
problem can be avoided by using tests that assesses processing speed independently of the use
of the hand (e.g. counting speed). Pollina did this to distinguish between reduced fine motor 
speed and cognitive slowing in LNB treated patients and found that the affected processing 
speed in these patients was independent of the hand function [94].
Typical tests for assessing processing speed are the TMT 5 and Digit symbol tests, both tests 
are translated into Norwegian, the Digit symbol test as part of the Wechsler Adult Intelligence 
Scale (WAIS) [98].
Memory functions and learning
Memory is the combination of processes where information is encoded, stored and retrieved, 
and consists of many components. Several models have been proposed to describe these 
processes, and although they differ, some major components seem to be consistent in current 
models.
Memory consists of long term memory and short term memory. Long term memory has an 
enormous capacity, and information can be actively brought up to the mind from previously 
gained information, sometimes for a lifetime. Recall or short term memory is like an echo of 
the immediate information gained, example a phone number or a message, allows recall for 
seconds only and is very limited without rehearsal capacity. Traditionally the explicit memory 
is assessed by NP tests, this part of the memory is available to the consciousness and can be 
actively brought to mind. It can be divided into memory for facts independent of context, like 
history, definitions and theories – semantic memory, and memory for events that are related to 
both time and space, the recollection of “what, where and when” of experiences we have had
– so called episodic memory. The other part of long term memory, implicit memory, is not as 
available for testing, it is more procedural and no- conscious, like to remember how to ride a
bike [99].
In NP research that includes individuals with LNB, the focus has mainly been on explicit 
memory, especially episodic memory. The tests of episodic memory often include free recall, 
cued recall and recognition of a list of e.g. words. Free recall is when a person has to 
remember a word list previously presented and recall as many words as he can. Cued recall is 
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tested when a hint, or a “cue word” is given that will remind the person what kind of words he 
has to remember, like “how many vegetables do you remember from the list presented”. 
Recognition is tested when a person has to point out the words or pictures form a previously 
presented list among other words or pictures that were not presented in the first list (based on 
familiarity). 
The Californian Verbal Learning Test (CVLT) is a test of episodic memory, widely used. It 
was the first clinical instrument that quantified multiple components of learning and memory 
and incorporated the principles from years of cognitive science. It tests verbal memory and 
verbal learning. It has also been used in many studies of outcome after LNB.  The Digit 
symbol test is primarily a test of processing speed, but also includes assessment of incidental 
visual learning and visual memory. 
Another much used memory test, the Wechsler Memory Scale (WMS), is also available in 
Norwegian. This test assesses both visual and verbal memory, but is much more time and 
effort demanding than CVLT-II.
The four neuropsychological tests we have used in our study (Californian Verbal Learning 
Test, Digit Symbol, Stroop and Trail Making Test) are presented in more detail in the method 
part of this thesis.
1.2.8 Studies of neuropsychological functioning after Lyme disease and Lyme 
neuroborreliosis
There are several studies on cognition after Lyme disease conducted during the last decades.
A review from 2000 covers the controlled studies in which standardized NP tests has been 
used, starting with the Krupp et al. study from 1991, and ending with the two studies by 
Pollina et al. from 1999 [100]. Again, the lack of European controlled studies on long term 
outcome after LD is striking. The Benke et al. study from 1997 is the only European 
controlled study with standardized NP tests that we are aware of [101]. Several US studies 
have included an IQ test or an IQ estimation [41;61;90;92;102;103]. In addition to the studies 
on cognition in LD from 1991 to 2008 included in Table 07, three US treatment studies using 
cognitive function as primary or secondary endpoints are listed in Table 08. The table 
includes information about NP tests used, IQ assessments and premorbid IQ estimations. 
35
Table 07. Studies including Neuropsychological (NP) testing in Lyme Neuroborreliosis 
(LNB) (except treatment studies, for these see Table 08) 
Study Material Design Assessments Main results
[90] Krupp et 
al.  1991
New York, 
USA
15  LD patients 6.7 
months after 
treatment with 
persisting 
complains
10 Healthy controls   
Retrospective 
Matched 
controls
TMT 
WAIS-R (IQ 
estimate)
Digit symbol
COWA 
WMS-R
SRT
LD treated patients scored worse 
on verbal fluency and memory 
tests, had more depression, with 
inverse effect on NP performance
[102] Kaplan 
et al.  1992 
USA
20 LNB patients 
years after 
treatment with 
memory and mood 
problems
11 depressed 
controls
11fibromyalgia 
controls
Retrospective 
Controlled 
CVLT
WAIS-R(IQ-
estimate)
WMS
LNB treated patients were more 
depressed, but NP deficits cannot 
be explained solely by this. LNB 
patients had deficits in delayed 
recall, visual reproduction and 
associated learning. (Long-delay 
free recall, trial 5 on CVLT, no 
association to depression, or 
anxiety)
[61] Shadick 
et al. 1994
Ipswich,
USA
38 LD patients 6.2 
years after 
treatment
43 Healthy controls
Retrospective  
controlled 
cohort study
TMT 
Stroop
Pegboard
CVLT
WMS
IQ estimate ( 
Shipley 
Abstraction)
LD treated patients scored worse 
on CVLT (Long delay recall)
LD treated patients scored worse 
on tests assessing executive 
functioning and processing 
speed.Correlated with delayed 
treatment , more anti-Bb
antibodies 
[101] Benke et 
al. 1995 
Austria
20 LNB patients 51 
months after 
treatment (not all 
received treatment) 
20  controls with 
other neurological  
problems without 
brain damage
Cohort study
Matched
controls 
CVLT
WAIS (Block 
design)
COWA
Reaction time
Ravens 
progressive 
matrices
LNB treated patients scored lower 
on tests assessing learning, verbal 
memory, mental flexibility, verbal 
associative function and 
articulation. CVLT list B caused 
significant cued and free recall 
problems.  Unimpaired: Intellect, 
psychomotor  tempo, sustained 
attention
[91] Bujak et 
al. 1996 
USA
23 LNB patients  
5.6 years after 
treatment
23  patients who 
recovered from LD 
Retrospective  
Matched 
controls
TMT
CVLT
WMS-R
LNB treated patients scored lower 
on tests assessing attention/ 
concentration/ and verbal and 
visual memory. More verbal than 
visual memory deficits
[92] Ravdin et 
al. 1996
USA
21 LD patients 15 
months after 
treatment
21 controls with 
osteomyelitis
21 Healthy controls
Prospektive
Controlled
CVLT
IQ  estimate
(National 
Adult Reading 
test)
LD treated patients had more 
verbal memory and learning 
deficits. They had as much 
memory problems as the 
osteomyelitis controls.  (Long 
delay free recall on CVLT, no 
association to depression or 
subjective complains)
[93] Gaudino 
et al.
1997
USA
38 LNB treated  
patients with 
fatigue                  
25 Chronic Fatigue 
Syndrome controls
Retrospective 
Controlled
WAIS-R
(Digit 
Symbol)
TMT
COWA
LNB treated patients scored 
worse on the Digit Symbol, verbal 
learning, verbal fluency and fine 
motor speed
36
56 Healthy controls SRT
WMS-R
Benton Visual 
Retention test
[94] Pollina et 
al.
1999
USA
16 LD treated 
patients
15 Healthy controls
Retrospective 
Controlled
Computer RT 
task 
Selective 
reminding test
IQ estimate( 
Shipley 
Vocabulary 
test)
LD treated patients scored lower 
on tests assessing processing 
speed and memory .More 
depression and fatigue, but these 
factors did not have any impact 
on NP performance
[103] Pollina 
et al. 1999
USA
25 LD treated 
patients with 
persisting 
complains
23 Healthy controls 
Retrospective
Controlled
Computer RT 
PASAT
TMT
Digit symbol
IQ estimate 
(ShipleyVocab
ulary test)
LD treated patients  group had 
cognitive slowing  independent of 
age, premorbid abilities, motor 
skill, and degree of depression 
[104] Svetina 
et al.
1999
USA
44 LD patient at“ 
second stage”
43 Healthy controls
Retrospectiv
Controlled
COWA
Boston 
naming test
CVLT
LD treated patient claimed to 
have naming problems, and a 
subtle naming deficit was found 
secondary to memory retrieval 
deficit 
[105] Kaplan 
et al. 1999 
USA
14  patients with 
Lyme 
encephalopathy 
(objective 
infection)
18 PLDS patients
15 Healthy controls 
Controlled 
matched
Gordon 
diagnostic 
system,
SRT
TMT
Digit symbol
Both LD patient groups reported 
memory problems, Lyme 
encephalopathy group scored 
lower on memory test. PLDS 
group scored lower on attention 
and psychomotoric speed tests. 
Depression did not correlate to 
memory scores 
[41] Kalish et 
al.
2001
Lyme, 
Connecticut, 
USA 
84 LD patients 20-
30 years after 
treatment
(25 Erythema 
Migrans,
31  Facial palsy, 
28  arthritis) 
30  neighbors 
Retrospective
Controlled
CVLT
COWA
Digit symbol 
IQ estimation 
(Shipley 
Hartford 
Institute of 
Living Scale)
No significant differences on NP 
performances between the 4 
groups
[106] Keilp et 
al.
2005
USA
81 LD  patients 
with cognitive 
problems 7 years 
after treatment
39 Healthy controls
Retrospective
Controlled
WAIS-III
WMS-III
LD treated patients scored worse 
on memory and processing speed, 
but had normal global processing 
speed scores. No association to 
depression/ prolonged treatment/ 
delayed treatment found
[107]
McAuliffe et 
al. 
2008
USA
25 LD adolescents 
24 months after 
treatment
25 Healthy controls
Retrospective
Matched 
controls 
WASI
WRAML-II
DKEFS
LD adolescents did score lower in 
tests assessing short term visual 
memory, short term and delayed 
verbal memory, recognition 
memory. They did have school 
problems
IQ; Intelligence Quotient, PASAT; Paced Auditory Serial Addition Test,  TMT; Trail Making Test, WAIS; 
Wechsler Adult Intelligence, COWA; Controlled Oral Word Association SRT; Selective Reminding test, CVLT; 
California Verbal Learning test, WMS ;Wechsler Memory Scale, WASI;Wechsler Abbreviated Scale of 
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Intelligence, WRAML; Wide Range Test of Memory and Learning, D-KEFS; Delish-Kaplan Executive 
Functional System
The studies of cognition in LNB have different inclusion criteria and designs, and various 
tests have been used to assess cognitive function, so comparisons of the studies are not easy.
The main impression is though, that some patients have cognitive functioning problems after 
LNB, even years after treatment. The studies have not revealed a specific cognitive deficit 
profile, but processing speed, memory and executive functions seem to be involved. There are 
until now no imaging studies that have shown parenchymal (CNS nerve tissue) changes that 
are specific for LNB [47] and repetitive and prolonged antibiotic treatment has not shown to 
improve cognitive function [64;66;67;108].
1.2.9 Pathophysiology of remaining complaints after Lyme neuroborreliosis
The pathophysiological explanation for remaining subjective and objective complaints after 
LNB is not known, but different theories have been discussed:
Slower response to therapy or incomplete resolution due to irreversible tissue damage:
Some patients have objective residual deficits like a partial facial palsy and/or subjective 
symptoms that may be due to slow resolution of the inflammatory process or irreversible 
tissue damage [41;52;109]. The study of Ljøstad et al. showed that patients with a higher CSF 
cell count and a higher CSF protein level had more complaints one year after treatment. It is 
possible that a more pronounced inflammatory process in these patients reflects a more 
aggressive infection that again causes more residual tissue damage [55].
Autoimmunity
Steere et al. have found that a few patients develop antibiotic-refractory Lyme arthritis after 
treatment that is most likely due to an autoimmune process triggered by the infection [110]. It 
has been discussed if an autoimmune process years after treated LNB can contribute to 
persisting complaints. This is not confirmed, but cross reactions of Bb specific antibodies with 
neuronal antigens are demonstrated [111] and a case report of autoimmune-mediated 
polyneuropathy in a LNB treated patient that responded well to immunoglobulin therapy is 
published by Rupprecht et al [112].
Endocrine dysfunction
Tuberculosis meningitis and various other infectious diseases can affect the endocrine system
and cause dysfunction of the hypothalamus and/or the pituitary gland. A recent Swedish study 
evaluated hormone levels in previously treated LNB patients with and without persistent 
symptoms and compared the results to a healthy control group. They did not find any 
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corticotrophic insufficiency or other serious hormonal dysfunction associated with PLDS 
[113].
Ongoing infection
In the treatment and diagnostic guidelines from Wormser et al. arguments for and against an
ongoing infection in PLDS patients are systematically evaluated [20]. The authors conclude 
that “There is no convincing biologic evidence for the existence of symptomatic chronic Bb
infection among patients after they have received recommended treatment regimens for LD.
Antibiotic therapy has not proven to be useful in PLDS, and is not recommended for patients 
with chronic (စ6 months) subjective symptoms after recommended treatment regimens for 
Lyme disease”.
Arguments against ongoing infection in these patients are that the Bb has not demonstrated 
antibiotic resistance, and there is no correlation between laboratory findings of inflammation 
and physical signs of disease in the treated LNB patients [20]. Bb can form cysts in vitro
[114], but this has not been shown in vivo, and it is not considered to have any clinical 
significance [20]. Further it has not been proved that prolonged and repeated treatment 
courses have resulted in longer standing improvement of PLDS symptoms (see Table 08)
[64;66;67;108].
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Table 08. Treatment studies of Post Lyme Disease Syndrome (PLDS)
Short form-36;SF-36, CalCAP; California Computes Assessment Package, AVLT; Rey Auditory Verbal 
Learning Test, BVRT; Benton Visual Retention Test, COWA; Controlled Oral Word Association Test, WAIS; 
Wechsler Adult Intelligence Scale, PASAT; Paced Auditory Serial Addition Test, TMT; Trail Making Test, FSS; 
Fatigue Severity Scale, AE; Adverse Event
In 2011 a US study of 158 patients with NP symptoms for at least 3 months and positive 
testing for Bb previously received a extended antibiotic therapy (intravenous ceftriaxone), and
reported improvement of cognition, arthralgias, myalgias and fatigue. This study did not 
include a control group, and did not demand intrathecal production of anti-Bb antibodies to 
prove the diagnosis of LNB. The outcome was assessed with a self-designed patient self-
Study Material Design Assessments Result
[64] Klempner 
et al. 2001        
[108] Kaplan et 
al. 2003
USA
78 seropositive LD 
patients with 
persistent symptoms
51 seronegative LD 
patients with 
persistent symptoms
Controlled 
treatment trial 
IV ceftriaxone 
30 days, 
doxycycline 
60 days 
/Placebo IV 
and oral
2001:Quality of 
life (SF-36)
2003:neurocognition 
(Symbol digit, 
calCAP, AVLT, 
BVRT,COWA)
No significant 
differences. 
[66] Krupp et 
al.  2003
Long Island,
USA
55  LD patients with 
persistent severe 
fatigue
Randomized, 
controlled 
treatment trial
IV 
ceftriaxone/  
placebo for 28 
days
Fatigue (FSS) and 
cognitive function 
(WAIS, PASAT, 
TMT) at 6 months   
No improvement in 
cognition. Temporary 
release fatigue. To severe 
AEs, treatment  not 
recommended
[67] Fallon et 
al. 2008
New York, 
USA
37 treated LNB 
patients with 
cognitive 
impairment 
20  matched 
controls 
Controlled 
randomized 
treatment 
study
10 weeks IV 
ceftriaxone vs. 
placebo
Quality of Life (SF-
36), fatigue (FSS) 
and neurocognition 
(TMT, Digit symbol, 
Stroop, COWA,
Buschke Selective 
Reminding Test,
Benton Visual 
Retention Test)
A improvement in 
cognition after 12 weeks 
was not present at 24 
weeks
Transient improvement 
of fatigue.
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administration symptom score with 28 separate questions about the severity of symptoms. 
They did not use standardized questionnaire for the assessment of fatigue, and they did not 
assess NP functioning.  The authors recommended treatment duration for 25-52 weeks for 
LNB with cognitive symptoms, but we think this study conclusion must be considered with 
care because of all the methodological weaknesses mentioned [115].
Co-infections with other tick borne microorganisms like Babesia, TBE or Anaplasma
The possibility of a more severe disease if the patient has been infected with more than one 
tick borne pathogen is discussed, but until now studies have not confirmed this
[64;67;116;117]. Symptomatic Anaplasma infections in humans appear to be rare in Norway; 
only two cases are documented, but a serological analysis of blood samples from Bb positive 
patients in Norway have shown that 10% are positive to both Bb and Anaplasma [118;119].
Between 1998 and December 2011 54 cases of tick borne encephalitis and no cases of human 
babesiosis are documented in Norway, but we have little knowledge about co-infections 
(MSIS 20.12.2011). 
Psychiatric explanations
It is known that infection with Bb may cause psychiatric symptoms [120]. It is also discussed 
if psychological factors and psychiatric comorbidity might be an underlying explanation of 
PLDS. Solomon et al. found that psychiatric impairment before an episode of LNB could lead 
to more chronic problems after treated LNB [121]. Hajec et al. screened psychiatric patients 
for anti-Bb antibodies and found a higher proportion of seropositive individuals among 
psychiatric patients than in a control group, but found no association between seropositivity 
and specific psychiatric diagnostic categories [122]. Hassett et al. found that patients 
suspected to have “chronic LD” had more psychiatric comorbidity as compared to healthy 
controls, and controls with another chronic disorder. Forty-five per cent of the chronic LD 
patients had a depression, and 25% of them had anxiety, but they did not find psychiatric 
comorbidity in all “chronic LD” patients. Therefore they concluded that the symptoms 
associated with “chronic LD” in this patient group could not be described as a purely 
psychiatric condition [123].
In summary studies of long term outcome after LNB are mainly conducted in the US, and the 
studies are not easy to compare to each other mainly because of different inclusion criteria. 
The studies have found reduced HRQoL, fatigue and various cognitive deficits in LNB 
patients, but the pathophysiology of this non-favorable outcome is not known. Repeated and 
prolonged antibiotic treatment does not seem to help. In Europe there is a lack of controlled 
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studies on long term outcome after LNB. This is problematic as the results of the US studies 
are not necessarily transferable to European patients, because the Bb genotype and the clinical 
human LD phenotype in the US differ somewhat from what we find in Europe.
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2. Aims of the study
The aim of this thesis was to investigate the long term outcome in European LNB treated 
patients regarding HRQoL, NP functioning and fatigue.  We also wanted to identify possible 
risk factors for a non-favorable long term outcome in LNB treated patient.
Study hypotheses
Before study start we hypothesized that, compared to controls, patients treated for European 
LNB 30 months earlier had:
x Reduced HRQoL 
x More cognitive deficits 
x More fatigue 
We also hypothesized that
x A non-favorable outcome after treated LNB could be predicted by factors like severity 
of the disease, time to treatment, comorbidity, gender, and sings of CNS infection
involvement before treatment.
These hypotheses were tested in paper I-III as follows:
Aim of paper I: To assess HRQoL in well characterized adult European LNB patients 30 
months after treatment in a case-control designed study. 
Aim of paper II: To compare NP functioning in a group of well characterized adult European 
LNB patients 30 months after treatment to a matched control group. 
Aim of paper III: To identify clinical, demographic or laboratory risk factors associated with a 
reduced HRQoL and fatigue 30 months after treatment in a cohort of  well caracterized adult 
European LNB patients.
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3. Material and methods
3.1 Study design
Paper I and II: Hospital based, age, gender and education level matched case-control follow-
up study 30 months after treatment.
Paper III: Cohort study from time of diagnosis and treatment to follow-up at 4, 12 and 30 
months.
3.2. Study population
Patients
From 2004 to 2008 we included 102 consecutive adult patients diagnosed with LNB in a 
randomized multicenter treatment trial conducted in the coastal areas of southern Norway. 
Out of these, 64 patients were recruited from two of the nine participating hospitals, covering 
the high endemic region of the Agder Counties. The 57 patients of the 64 patients who were 
included in the treatment trial between May 2004 and December 2007 were invited to the 
current follow-up study 30 (27-34) months after treatment. The inclusion criterion was 
definite or possible LNB according to criteria shown in Table 09.
Table 09. Diagnostic criteria used for inclusion of Lyme neuroborreliosis (LNB) patients in 
the treatment and follow-up study
Definite Lyme neuroborreliosis
All three criteria fulfilled
Possible Lyme neuroborreliosis
Criteria 1 and one or more of  a- d
1. Neurological symptoms suggestive 
of LNB without other obvious reasons
2. Lymphocytic pleocytosis          
(> 5 leucocytes/mm3) 
3. Intrathecal anti-Borrelia antibody 
production 
      1. Neurological symptoms suggestive 
            of LNB without other obvious reasons
a. Lymphocytic pleocytosis                     
(> 5 leucocytes/mm3)
b. Intrathecal anti-Borrelia antibody 
production 
c. Anti-Borrelia antibodies in serum                    
d. Verified erythema migrans during
          the past four months 
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These diagnostic criteria comply with the diagnostic criteria from the EFNS guidelines (see 
Table 03 in background part of thesis) [25]. Thirty-four patients (68%) had definite and 16 
(32%) patients had possible LNB according to these criteria. 
Participants were invited by letter, and non-responders were phoned once. Fifty patients 
consented to participate and were included and analyzed.
Non-participants: Out of practical and logistically considerations we did not include all the 
participants from the treatment trial. Neither the patients from the treatment trial who were not 
recruited to the follow-up study, nor the seven patients who were invited but not included, 
differed from the 50 included patients regarding treatment or severity of the disease before 
and 4 months after treatment. The seven invited non-participants were in the mean 5 years 
older than the included patients.
The patient’ pre-treatment characteristics are presented in Table 10.
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Table 10. Lyme neuroborreliosis patient’s characteristics before treatment
Mean age (years ) 53 (SD=13) (range 18-77)
Gender (male) 29 (58%)
Coexsisting diseases 25 (50%)
Psychological diseases, past or present 10 (20%)
Tick bite past year 30 (60%)
Erythema migrans last year 11 (22%)
Neuroborreliosis diagnosis 
definite 
possible
34 (68%)
16 (32%)
Pre-treatment Symptom duration (weeks) 9.2 (SD=19) (range 1-104)
Symptom duration> 6 weeks 10 (20%)
Symptom duration >6 months 4 (8%)
Mean CSF cell-FRXQWFHOOVPPQRUPDO 187 (SD=255) (range 0-1176)
Mean CSF protein level  g/L (normal 1,5-5,0) 1.22 (SD=0.73) (range 0.3-2.8)
Mean clinical score (range 0-64) 8.3 (SD=4.3) (range 3-21)
Mean subjective score (range 0-12) 4.8 (SD=2.6) (range 1-11)
Mean objective findings 3.5 (SD=2.5) (range 0-11)
Bannwart syndrome 40 (80%)
Radiculitis 20 (40%)
Facial palsy             
unilateral
bilateral
7 (14%)
1 (2%)
Other cranial neuropathies 4 (8%)
Plexopathy 1 (2%)
Cerebral symptoms 4 (8%)
Ataxia 2 (4%)
Myelopathy 1 (2%)
Pareses in extremities 8 (16%)
Subjective complaints alone 5 (10%)
Treatment option              
doxycycline
ceftriaxone
26 (52%)
24 (48%)
Controls
Each LNB treated patient invited a control person at the time of follow-up, matched for age, 
education level and gender. If a patient failed to bring a control person, another patient was 
asked to bring two. The only exclusion criterion for the controls was previously
46
acknowledged LNB. Serological testing of the controls was not done as 15-20% of the 
inhabitants of the Agder Counties are known to have anti-Bb antibodies without any history of 
LNB [14].
Patient and control characteristics at follow up are shown in Table 11.
Table 11. Lyme neuroborreliosis treated patients and controls characteristics at follow-up 30 
months after treatment
LNB treated patiens (n=50) Controls (n=50)
Age years (range) 55 (21-76) 56 (20-78)
Gender male 29 (58) 29 (58)
Married/partner yes 44 (88) 44 (88)
Employed 30 (60) 34 (68)
Secondary education 0-3 years 25 (50) 23 (46)
Secondary education 4-7 years 15 (30) 13(26 )
Secondary education >7 years 10 (20) 14 (28)
Coexisting somatic diseases
Total n (%)
Multiple sclerosis
Parkinson’s disease
Diabetes mellitus
Atherosclerosis
Cancer
Disabling headache
Tinnitus
Head trauma
Hypertension
Asthma/COLD**
Fibromyalgia
Post-polio
Muscle pain/ischialgia
Previous/present psychiatric diseases
25 (50)*
1 (2)
1 (2)
5 (10)
4 (8)
4 (8)
0
0
0
5 (10)
3 (6)
2 (4)
1 (2)
4 (8)
10 (20)
29 (58)*
0
0
3 (6)
2 (4)
1 (2)
1 (2)
1 (2)
1 (2)
2 (4)
5 (10)
2 (4)
1 (2)
10 (20)
8 (20)
Data are number of patients (%), unless otherwise stated.*some participants had more than one disease. **
COLD = chronic obstructive lung disease
One patient had Multiple Sclerosis and one Parkinson’s disease. In those patients the 
neurological findings attributed to LNB were new and accompanied by typical laboratory 
findings, and the criteria for definite LNB were fulfilled. The cancer diseases observed in both 
groups were treated and cured 10-20 years earlier except for in two patients, one who had a 
stable frontal astocytoma, and one patient who was diagnosed with an advanced cancer 
prostate between the treatment for LNB and follow-up. 
3.3 Clinical and laboratory variables
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Demographic, laboratory and clinical data was collected pre-treatment and at 4, 12 and 30 
months after treatment (see figure 02).
Figure 02. Time axis “European neuroborreliosis. Long term follow up” study
Diagnosis and 
treatment
X 
Interview X X X X
Neurological
examination
X X X X
Spinal and 
blood tap
X X ( n=42) X (n= 33) X (n=29)
SF- 36 X
FSS,MADRS SAS, 
MMS
X
NP testing X
SF-36: Short Form-36, FSS: Fatigue Severity Scale, MADRS : Montgomery and Åsberg 
Depression Rating Scale, SAS: Starkstein  Apathy Scale, MMS: Mini Mental State, NP: 
Neuropsyhological
Baseline 
and 
treatment
Follow-up
4 months
Follow-up
12 months
Follow–up 
30 months
A composite clinical score was used to assess subjective complaints and clinical neurological 
findings, (range 0-64, 0= no complaints or findings) [39]. A clinical score at 30 months of 
was regarded as complete recovery, and >1 as non-complete recovery.The clinical score data 
were normally distributed (see table 12).
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Table 12 Composite clinical score in Lyme neuroborreliosis patients
Clinical outcome score is the sum of subjective and objective findings. Each item is scored 0 = no, 1 = mild, 2 =
severe (maximum total score 64). * Left and right sides scored separately
All participants were asked the following at the 30 month follow up: “Do you have any other 
diseases?” ” Do you have, or have you previously had, psychological distress that made it 
necessary to use pharmacological therapy, consult a therapist or take sick leave?” ” Is fatigue 
an every-day problem for you?” “Did you recover completely from LNB?” We reviewed 
individual hospital records to confirm the patients past medical history.
To assess depression we used the Montgomery and Åsberg Depression Rating Scale 
(MADRS range 0-60. Scores 0-9 indicate no depression, scores 10 -19 indicate mild 
depression that does not need treatment, scores 20-34 indicate moderate depression that needs 
to be treated and scores > 35 indicate severe depression) [124]. This is a frequently used, 
reliable and validated questionnaire available in the Norwegian language. 
To assess apathy we used the Starkstein Apathy Scale (SAS range 0- EHVW4= 
significant apathy) which is translated into Norwegian [125].
Clinical score in LNB patients.
Subjective complaints
(maximum score = 12)
Objective findings
(maximum score = 52)
Malaise
Fatigue
Pain
Memory problems
Concentration difficulties
Paresthesia
Facial palsy *
Reduced hearing*
Vision loss l/r
Reduced sensibility in face* Paresis of eye 
muscles*
Other cranial neuropathies  
Tremor
Ataxia
Nuchal rigidity
Confusion
Other CNS findings
Radiculopathy truncus *
Radiculopathy arm*
Radiculopathy leg*
Paresis arm*
Paresis leg*
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To grade the cognitive functioning we used the Mini Mental State (MMS range 0-30, 30=no 
problems) [126] which is a reliable and validated test translated into Norwegian. 
Laboratory variables
The patients underwent a lumbar puncture pre-treatment (n=50), at 4 months (n=42), at 12 
months (n=33) and at 30 months (n=29) (see Figure 02). We analyzed cell-count, protein 
level, anti-Bb antibodies, oligoclonal bands, and CXCL-13 level in the CSF. Anti-Bb IgM and 
IgG antibodies in serum and anti-Bb IgG antibodies in CSF were first analyzed by an 
Enzyme-Linked Immunosorbent Assay (ELISA ) test using Bb (PKo strain) as antigen, from 
November 2008 also including the VlsE antigen (Enzygnos Lyme link VIsE/IgG (Siemens, 
DADE Behring, Marburg, Germany).
CSF was examined for anti-Bb IgM antibodies and for intrathecal antibody production with 
the IDEIA Bb IgM and IDEIA Lyme Neuroborreliosis kit (DakoCytomation,
Cambridgeshire, UK) using purified native flagella from the B. Afzelii DK1 strain as antigen. 
In these assays corrections for impairment of blood-brain barrier is unnecessary [44], and 
intrathecal production of antibodies is detected when, according to the manufacturers`
recommendation, the antibody index of: OD optic density) CSF /OD serum x (OD CSF -OD
serum) is > 0.3. For the CSF CXCL-13 detection we used an ELISA test (Quantikine, R&D 
Systems, Minneapolis, US). Based on the findings in a previously published study 
concentrations < 4 pg/ml were stated as not detectable (0 pg/ml) [46]. The patients were also 
tested for Tick Borne Encephalitis (TBE) virus antibodies. We did not test for Anaplasma, but 
none of the patients had a clinical picture or blood count suggestive of Anaplasma infection.
All anti-Bb antibody negative patients were tested for Herpes simplex, Varicella Zoster and 
entero-virus by Polymerase Chain reaction (PCR) of CSF. 
3.4 Outcome measures
HRQoL
At inclusion in the follow-up study all participants fulfilled the  Norwegian translation of the 
HRQoL questionnaire SF-36 version 2, a short generic, 36 item questionnaire which measures 
eight multi-item dimensions covering functional status, well-being and over-all evaluation of 
health. The SF-36 is reliable, valid, and the most widely used questionnaire for assessing 
HRQoL in both neurological and other diseases. Version 2 relates its questions to the last four 
weeks. There are Norwegian normative data available [127]. Our primary outcomes were 
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mean scores in the two SF-36 summary measures; Physical Component Summary (PCS) and 
Mental Component Summary (MCS) scores. PCS is summarized from the four physical 
health dimensions; physical functioning (PF), role physical (RP), bodily pain (BP) and 
general health (GH), and MCS is summarized from the four mental health dimensions; vitality 
(VT), social functioning (SF), role emotional (RE) and mental health (MH) (se Figure 03). 
The sumscores PCS and MCS are calculated from the 8 dimensions and related to normative 
data, in this study the Norwegian Normative data. The score range is 0 –100, with 100 as the 
best possible score [128].
Figure 03 Sort Form-36 Measurement model (adapted from Ware JE.SF-36 Health Survey 
Update 2000 Spine volume 25 3130-3139) [128]
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Vigorous Activities    
Moderate Activities     
Lift Carry Groseries     
Climb Several Flights     
Climb One Flight  Physical 
Functionning(PF) 
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Mental Health  
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It was not possible to calculate PCS in one control and one patient and MCS in one patient
because of missing data on three of the SF-36 subscale dimensions. We decided not to impute 
data because we were able to use 48 full sumscores in patients and controls.
Secondary outcomes were the scores on the 8 dimensions of the SF-36. Score differences in 
the 8 dimension groups of 5-10 points can be regarded as modest and 10-20 as moderate 
changes [129].
Fatigue
The Fatigue Severity Scale (FSS) is a much used brief and simple self-assessment 
questionnaire which is translated into Norwegian, has satisfactory internal consistency, and is 
sensitive to clinically significant changes [76;130]. Each of the nine statements are rated on a 
scale from 1 (strong disagreement) to 7 (strong agreement) (see table 13). The individual FSS 
score is the mean of the scores on the 9 statements, ranging from 0-7 (0 =no problems) and 
assesses the effect of fatigue on activities of daily living. We defined a score > 4 as significant 
fatigue and a score >5 as severe fatigue. 
Table 13. Fatigue Severity Scale (FSS), Norwegian translation
FSS
Siste uke har jeg følt at Skår
1. Mitt pågangsmot blir dårligere når jeg er utmattet 1 2 3 4 5 6 7
2. Jeg blir fort utmattet ved anstrengelser 1 2 3 4 5 6 7
3. Jeg har lett for å bli utmattet 1 2 3 4 5 6 7
4. Utmattelse nedsetter min fysiske funksjonsevne 1 2 3 4 5 6 7
5. Utmattelse skaper ofte problemer for meg 1 2 3 4 5 6 7
6. Utmattelse fører til at jeg har dårlig fysisk utholdenhet over lengre tid 1 2 3 4 5 6 7
7. Utmattelse virker negativt inn på mine gjøremål og forpliktelser 1 2 3 4 5 6 7
8. Utmattelse er ett av mine tre mest plagsomme symptomer 1 2 3 4 5 6 7
9. Utmattelse virker negativt inn på mitt arbeid, min familie og mitt øvrige sosiale liv 1 2 3 4 5 6 7
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NP functioning
Cognitive assessment in patients and controls was carried out by one experienced neurologist 
(RE).  All participants were informed that the NP tests assessed different aspects of cognition, 
like memory and attention, and they were encouraged to perform their best in every test. A 
trained neuropsychologist blinded to group adherence scored the NP tests. The NP tests were 
administered in a fixed order, but short breaks were permitted if needed. The NP testing lasted 
between 1.5 and 2.5 hours and was administrated between 09 and 14 all in the same day. The 
neurological examination and the lumbar punctures were done after the NP testing.
The NP test selection was based on previous relevant studies [61;106;108]. Tests that had 
been translated into Norwegian, had previously been used on a Norwegian population, and 
known to be reliable and validated were included (Stroop, TMT, Digit symbol and CVLT).
Attention/Executive functions
The trail making Test (TMT 1-4) assesses attention and flexibility in solving problems in
visual-motor tasks. The first condition is visual scanning that requires the participant to cross 
out a number among an array of letters and numbers. In the second condition numbers must 
be connected in rising order. The TMT 3 requires the participant to connect letters in 
alphabetical order. The fourth condition is the primary attention/executive function task; the 
participant must switch between two sets of rules by connecting numbers and letters in correct 
order. Raw scores are the number of seconds taken to complete each task [99].
TMT 1-4 instructions: 
TMT 1: Tick a specific number among an array of letters and numbers.
TMT 2: Connect numbers in rising order. 
TMT 3: Connect letters in alphabetical order. 
TMT 4: Connect numbers and letters in correct order.
The color-word interference, task 1-4, is an adapted version of the Stroop test that assesses the 
ability to inhibit a prepotent reaction (impulse control), and the ability to switch between 
rules. The first condition requires the participant to name colors, and in the second condition 
the task is to read color names. In the third condition the participant is required to inhibit the 
reading and focus on the ink color in which the word is written. In the last condition the 
participant is asked to name the ink color on all words except those that are placed within a 
square, those words must be read.  The last two conditions are the primary attention/executive 
tests and require both the inhibition of reading and the ability to switch between rules. Raw
scores are the time (seconds) used to complete the tasks [99].
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Stroop1-4 instructions:
Stroop 1: Name colors. 
Stroop 2: Read color names.  
Stroop 3: Avoid reading the word and instead name the ink color in which the word is written.  
Stroop 4: Name the ink color on all words, except those placed within a square, which should be read.  
Processing speed
The Digit Symbol task is part of the Wechsler Adult Intelligence scale (WAIS-III), and 
measures processing speed. It requires the participant to copy symbols paired with numbers 
during a 120 seconds interval. Raw scores are the number of correctly copied symbols [99].
Digit symbol test instructions:
Copy symbols paired with numbers.
The fifth condition of the TMT (TMT 5) measures motor speed by asking the participant to 
draw a line as fast as possible. Raw score is the time (seconds) used to complete the task [99].
TMT 5 instructions:
Draw a line between dots as fast as possible. 
Memory assessment
Visual memory and incidental learning was assessed by using the Digit symbol test free and 
cued recall and recognition. First, a row of symbols has to be combined with the numbers just 
copied in the first condition of this test. Recall condition was included by asking the 
participant to write down all of the symbols they could remember.
Digit symbol cued and free recall instructions:
Digit symbol cued recall test:  Combine symbols and numbers recalled from the digit symbol test. 
Digit symbol free recall test: Write down all symbols recalled from the digit symbol test.
The California Verbal Learning Test (CVLT) version II assesses verbal learning, short and 
long term memory, as well as recognition, through oral presentation of word lists that are to 
be learned during 5 repetitions. A second list is presented as a distracter once, and the 
participant has to recall the original list, in free and cued manner (short recall). After a 20 
minute brake, the list must be recalled again, and at the end there is a recognition test (long 
recall). Raw score is the number of words recalled [131].
The learning effect in CVLT is represented by the repetition of the word list 5 times, and the 
test person is supposed to remember more words the last time as he did the first time. 
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CVLT instructions:                                                                                                                     
CVLT 1-5: Recall the list of words                                                                                                                      
CVLT list B: Recall a second list presented once                                                                                                         
CVLT free and cued short recall: Recall the original list                                                                                          
CVLT free and cued long recall: Recall the original list after the break.
A problem to consider in every test situation is the level of individual effort. A person tested 
can be tempted to perform sub-optimally because of potential personal benefits, or to “please” 
the researcher. The optional trail of the CVLT-II, long delay forced-choice recognition, was
included to examine the degree of individual effort: 
CVLT-II, long delay forced-choice recognition instruction:
Pick the word from the original list among two different words presented immediately after the Long delay test. 
The global NP sumscore
The four NP test in our test panel consisted of 23 subtasks, and we calculated a global NP 
sumscore expressing the number of NP subtasks with scores of -1 SD or more from the mean 
in the control group (range 0-23). 
A challenge connected with the use of NP functioning assessments is that statistically lower 
results in one group compared to another does not necessarily have clinical consequences. To 
grade the severity of the results we categorized the global NP sumscores into three groups
(see table 14).
Table 14 Neuropsychological tests sumscore, degree of severity
Normal: 1--1 SD from the mean sumscore in the control group)
Deficit: 6-8 (>1--SD from the mean sumscore in the control group)
Impairment: 9-23 (>2- SD from the mean sumscore in the control group).
Normal: Scores between mean and -1SD may also have an impact on a person’s daily 
functioning, but to assess this, an individual evaluation is necessary. 
Deficit: This implies that the person is not able to perform the task at hand at the level 
expected, and a deficit will often  have consequences for daily life activities, for example at 
work/ school.
Impairment: The test person has major problems in performing the test/task at hand, or is not 
able to perform the task at all. NP impairment will cause functional problems in everyday life.
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Missing data were dealt with by imputing the mean score from the respective patient or 
control group. If the scores were missing due to inability to perform the test at hand, we 
imputed the lowest obtained score in the respective group. Four patients missed in average 2.5 
of the 23 subtasks, and four controls missed on average 1.5 of the 23 subtasks. 
3.5 Statistics
Sample Size
Based on the results from previous studies we decided in advance of study start that a group 
difference of 7% in the SF-36 PCS and MCS scores between the two groups would be of 
clinical interest to detect [64]. With a two-sided test and a significance level of P< 0.05, 36 
participants were required in each group to reject a null hypothesis of no difference with 80%
power. To compensate for drop-outs and non-evaluable tests and questionnaires, we planned 
to enroll 50 persons.
Statistics used in paper I-III
Paper I: The groups were compared by using student t-test (continuous data) and Chi-square 
test (categorical data). P-values <0.05 were regarded as statistically significant. The results are 
reported as mean scores with SD or proportions.
Paper II: Because of the matched one-to-one cases study design we used paired t-tests for 
normally distributed continuous data and Wilcoxon signed-rank test for paired continuous 
data that were not normally distributed, and McNemar test for paired categorical data.  P
<0.05 were regarded as statistically significant. The results are reported as mean raw scores 
with SD or proportions.
To present a profile of the test results based on a dimensionless quantity, we transformed the 
test results of each of the NP-23 subtest raw scores into a Z-score. The Z score represents the 
distance between the patients’ raw score and the mean in the control group (see Table 15).
Table 15. Definition of the Z score
Z score: (Zi=(Xi-Zcon)/SDcon where  Zi is the individual Z score of the  ith patient, Xi is the individuals test raw 
score, Zcon is the mean test result of the control group and SDcon is the mean SD of the control group.) 
The global NP sumscore (see above) was correlated to other findings by using Pearson’s 
correlation coefficient for continuous data and Mann-Whitney test for categorical data.
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Paper III: First we did univariate analyses for possible predictors using Pearson’s correlation 
for continuous variables and student t-test for comparing means. Education level was split 
into 3 levels and analyzed with Analysis of Variance (ANOVA). To be able to do a 
simultaneous assessment of multiple potential risk factors, all variables with P were 
included stepwise in a multiple linear regression model, one model for each of the three 
outcomes, PCS, MCS and FSS. Because of missing data the CSF variables were analyzed 
separately. The results are presented with B-coefficient and 95% Confidence Interval (CI). 
For clinical implementation of the models, we also presented the coefficient of determination, 
R2, which indicates how much of the variance in the outcome that is explained by the final 
model. 
3.6 Ethics
The participants in the study should be protected from physical and psychological harm. 
Lumbar punctions might theoretically cause harm, and the controls were not asked to go 
through a spinal tap. At our hospital normal procedures require an LNB patient to go through 
a lumbar punition before treatment initiation, and commonly a second spinal is done to 
evaluate the treatment effect after some time. The EFNS guidelines include the detection of 
intrathecally produced anti-Bb antibodies to diagnose definite LNB [25]. We regard the risk 
of causing harm to the patients as minimal, but if the patients declined to do go through spinal 
taps at the follow-up, this was of cause respected, and several patients did decline. 
The NP function assessments might have caused a mild psychological stress to some of the 
participants. Breaks were allowed when necessary, and the investigator informed the patients 
about the possible stressing effects of the NP tests. There was time to discuss the tests before 
and after assessment. If the controls scored poor on the tests they were advised about further 
diagnostics and treatment. The patients` general physicians were informed about the testing, 
and received information about test results.
When the patients and controls were asked to participate in the study, they were informed 
about the purpose of the study and the right to withdraw their participation at any time. Oral 
and written information were given.
All participants gave written informed consent. The study was approved by the Regional 
Committee for Medical Research Ethics in Southern Norway, and by the Norwegian Data 
Inspectorate.
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This trial is a follow-up study on the treatment trial registered with ClinicalTrials.gov number 
NCT00138801
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4. Summary of Results
Paper I: European Neuroborreliosis: A controlled Quality of Life study 30 months after 
treatment.
We found that HRQoL assessed with the SF-36 was reduced in 50 LNB treated patients 
compared to 50 matched controls. The group differences were 14% in mean PCS score and 
9% in mean MCS score (PCS 44 (SD=9) vs. 51 (SD=6) P< 0.001, MCS 49 (SD=11) vs. 54 
SD=6), P=0.001), both well above the pre-specified lower limit of 7% . The LNB treated 
patients scored worse than the controls on all the sub-dimensions on the SF-36 except bodily 
pain.
More LNB treated patients than controls reported fatigue to be an every-day problem (25 
patients (50%) vs. 8 controls (16%), P= 0.001). Out of the 50% of patients with subjectively 
reported IDWLJXHKDG)66VFRUHV The 16 LNB patients who reported severe fatigue 
(n=16) had higher FSS scores (mean=5.6 (SD=1.1) versus the LNB patients reporting a little 
fatigued (n=9) (mean 2.7 SD=0.9). This difference was significant (P<0.000). We found more 
patients than controls with significant fatigue (21 vs. 5 VFRUHGRQWKH)663) and 
severe fatigue (13 vs. 2 VFRUHGRQWKH)663 . The two controls with severe fatigue 
had other conditions commonly associated with fatigue, post-polio syndrome and chronic 
disabling cluster headaches, respectively.
There was no difference between the groups in the MMS scores.
The mean MADRS scores differed between LNB treated patients and controls (3.1 (SD=4.9) 
vs. 0.8 (SD=1.8), P=0.003), but the scores were below cut-off for depression in both groups 
and we did not consider the difference to be of clinical interest. One of the patients reached a 
MADRS score of 21 indicating a moderate depression in need of treatment. This participant 
suffered from relapsing depressions years before she got an LNB infection. We found no 
difference in mean MADRS scores between the patients reporting non-complete recovery and 
patients reporting complete recovery at 30 months.
The mean SAS score also differed between the groups (13 (SD=4) vs. 11(SD=4), P=0.016), 
but the scores were below cut-off for clinically significant apathy in both groups and we did 
not consider this difference to be of clinical interest either.  We found no differences between 
the proportion of LNB treated patients and the proportion of controls that scored above the 
cut-off for significant apathy of 14 on the SAS (18 vs. 17, P=0.301). The primary and 
secondary endpoints are presented in Table 16.
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Table 16. Primary and secondary endpoints in paper I, Quality of Life after treated Lyme 
neuroborreliosis
*The possible score range is 0-100. An increase in scores indicates an improvement in function.SF-36; Short
Form-36, Health Related Quality of Life assessment questionnaire.  SD; Standard Deviation, FSS ;Fatigue 
Severity Scale, MADRS; Montgomery and Åsberg Depression Rating Scale, SAS; Starkstein Apathy Scale; 
MMS ;Mini Mental State
Fourteen of our LNB treated patients had neurological findings. These findings are listed in 
Table 17.
Questionnaires LNB treated patients (n=50) Controls (n=50) P-value
SF-36 sum scores:          
PCS Physical component 
MCS Mental component
44(9)
49(11)
51(6)
54 (6)
<0.001
0.010
SF – 36 subscores*
Physical functioning, mean 
Role physical
Role emotional
Bodily pain
General health
Vitality
Social functioning
Mental health
80 (17)
56 (43)
80 (34)
66 (29)
69 (21)
51 (22)
84 (25)
80 (15)
90 (11)
82 (31)
93 (17)
75 (19)
84 (14)
71 (14)
95 (10)
86 (11)
0.001
0.001
0.027
0.116
<0.001
<0.001
0.005
0.035
MADRS 3.1 (4.9)* 0.8 (1.8)* 0.003*
FSS 3.5 (17) 2.1 (10) <0.001
MMS 28 (1.1) 29 (0.6) 0.106
SAS 13 (4)* 11 (4)* 0.016*
Reported subjective complaints
Malaise 
Fatigue
Pain
Memory problems
Concentration difficulties
Paresthesias
Number of patients (%)
11 (22)
25 (50)
16 (32)
23 (46)
17 (34)
17 (32)
Number of controls(%)
0
8 (16)
21 (42)
5 (10)
4 (8)
7 (14)
<0.001
0.001
0.408
<0.001
0.003
0.034
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Table 17. Number of Lyme neuroborreliosis patients with neurological findings 30 months 
after treatment. (N=50). Ten patients had more than one finding
Facial palsy 3
Reduced hearing 1
Reduced sensibility in the face 3
Anisocoria 1
Tremor 2
Ataxia 2
Nystagmus 2
Radiculopathy 6
Arm/leg paresis 4
Post-hoc and subgroup analyses
The 14 LNB treated patients 28% with neurological findings 30 months after treatment scored 
lower on PCS, but not on MCS as compared to those without persistent findings (PCS =38 
(SD=8) vs. 47 (SD=9), P=0.003) MCS =48 (SD=12) vs. 53 (SD=10), P=0.2), and they had a 
higher FSS score (4.3 (SD=2.0) vs. 3.1 (SD=1.8), P=0.045).
The 22 LNB treated patients that reported persisting complaints (44%) had a lower mean PCS 
score (37 (SD=7) vs. 50 (SD=8), P=0.001), and FSS score (4.8 (SD=2) vs. 2.4 (SD=2) P<
0.001) but a comparable MCS score (47(SD=10) vs. 51 (SD=12),Pp=0.3) to the 28 (%) LNB 
treated patients reporting complete recovery.
The LNB treated patients who reported complete recovery had the same HRQoL as 
the controls in term of PCS, MCS and FSS scores. 
There were no differences in mean PCS and MCS scores between patients with definite LNB 
(n= 34) and patients with possible LNB (n=16), (PCS 46 (SD=9) vs.43 (SD=12)P=0.5),
MCS (50 (SD=12) vs. 52 (SD=11), P=0.4), or between patients treated with ceftriaxone and 
patients treated with doxycycline (PCS (45 (SD=11) vs. 44 (SD=9) P=0.6), MCS (48 (SD=13) 
vs. 52 (SD=10), P=0.2).
We found a correlation between FSS scores and PCS and MCS scores in the LNB treated 
patient group (PCS: Pearson’s correlation coefficient -0.597 95% CI-0.753- -0.377, P<0.001, 
MCS: Pearson’s correlation coefficient-0.468 95% CI -0.663- -0.213, P= 0.001), and in 
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controls (PCS: Pearson’s correlation coefficient =-0.392 95% CI-0.608—0.122, P=0.005, 
MCS: Pearson’s correlation coefficient-548, 95% CI-0.72—0.313 , P<0.001).
Paper II. European Neuroborreliosis: Neuropsychological findings 30 months post 
treatment.
We found that patients treated for LNB scored lower on tests assessing executive/attention 
functions (Stroop 4), processing speed (TMT5) visual (Digit Symbol recall) and verbal 
memory (CVLT list B) as compared to matched controls, and our hypothesis of cognitive 
deficits after treated LNB was confirmed. Mean NP test results are presented in Table 18.
Table 18. Neuropsychological test results in treated Lyme neuroborreliosis patients (n=50) 
and controls (n=50) 30 months after treatment. Numbers are raw scores (Standard Deviation)
TMT; Trail Making Test, CVLT; California Verbal Learning Test
Function Measure Patients Controls P-
value
Executive TMT 2 (seconds) 39.0 (18.2) 34.8 (14.1) 0.202
Functions TMT 3 (seconds) 46.9 (38.6) 39.2 (21.5) 0.146
TMT 4 (seconds) 101.4 (55.1) 101.9 (46.3) 0.332
Stroop 1 (seconds) 31.6 (7.4) 30.6 (6.8) 0.558
Stroop 2 (seconds) 23.0 (4.9) 22.0 (3.7) 0.312
Stroop 3 (seconds) 64.8 (24.1) 59.2 (17.6) 0.102
Stroop 4 (seconds) 77.6 (30.1) 67.0 (16.3) 0.015
Processing speed Digit symbol (number of 
symbols.)
41.8 (12.8) 45.5 (11.5) 0.060
TMT 5 (seconds) 28.4 (9.7) 19.2 (6.7) 0.004
Visual memory Digit symbol, free recall 
(number of symbols )
6.6 (1.6) 7.2 (1.3) 0.038
Digit symbol cued recall 
(number of symbols )
9.7 (4.7) 10.6 (4.6) 0.261
Number of words 
recalled (SD)
Number of words 
recalled (SD)
Verbal memory CVLT trail 1
CVLT trail 2
CVLT trail 3
CVLT trail 4
CVLT trail 5
CVLT trail 1-5
CVLT list B 
CVLT Short delay 
CVLT Short delay cued 
CVLT Long delay 
CVLT Long delay cued
5.72 (1.9)
8.18 (2.4)
9.44 (2.4)
10.24 (2.1)
11.02 (2.4)
44.60 (9.1)
4.68 (1.9)
9.36(3.4)
11.58 (2.5)
10.34 (3.4)
11.50(3.4)
5.58 (2.0)
8.86 (2.7)
9.96 (2.8)
11.12 (2.6)
11.46 (2.6)
46.98 (11.5)
5.50 (2.0)
10.18 (3.1)
11.33 (4,00)
11.14 (3.1)
11.66 (3.4)
0.845
0.206
0.443
0.094
0.412
0.295
0.014
0.255
0.780
0.426
0.780
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None failed the CVLT long delay forced-choice recognition test, indicating adequate test-
effort in all participants.
The pattern of the NP deficits among our LNB treated patients was characterized by reduced 
impulse control, reduced processing speed and poorer ability of verbal learning. More patients 
WKDQFRQWUROVVFRUHG-1 SD of the mean in the control group on processing speed (TMT 5) 
and visual memory (Digit Symbol recall), 14 vs. 7 (P=0.046) and 10 vs. 3 P=0.038), 
respectively.
The Z score profile demonstrates that the patients scored lower in all subtasks, except two
(CVLT1 and CVLT short delay cued) and reflects a trend towards general lower test scores in 
the patients (see Figure 03).
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Figure 03. Patients neuropychological test results displayed as z-scores, i.e. standard
deviation above or below the mean in the control group. Y=0 is mean in control group.
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In order to investigate the clinical implications of the NP test scores further, we calculated the
global NP sumscore expressing the number of NP subtasks with scores -1 SD from the mean 
in the control group.  There was no difference between the patient group and the control group 
regarding normal NP functioning (0-13VXEWHVWZLWKVFRUHV-1 SD from mean sumscore in 
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control group) or NP deficits (6-8 NP subtest with scores >-1SD- -2 SD from the mean 
sumscore in the control group), but more patients than controls had an NP impairment (9-23
NP subtests with scores >-2 SD from the mean in the control group). The global sum score 
severities categories are presented in Table 19.
Table 19. Global NP sumscore categories
The histogram of the global NP sumscores in the patient and the control group demonstrates
that a small group of LNB patients had scores indicating cognitive impairment, and that most 
patients scored comparable to the controls (Figure 05). One control person had a global NP 
sumscore indicating NP impairment. In this person we suspected Alzheimer disease, and gave 
advises about further diagnostics and treatment. 
)LJXUH1XPEHURI1HXURSV\FKRORJLFDO13VXEWDVNVFRUHV-1standard deviation (SD) 
from the mean in the control group in Lyme neuroborreliosis (LNB) treated patients and 
controls (range 0-23). LNB treated patients 3.9 (4.2) Controls 2.6 (3.1)
NP sumscore categories Patients 
n=50
Controls 
n=50
P-value
Normal  n (%) 38 (76) 45 (90) 0.067
Deficit  n (%) 4 (8) 4 (8) 1.000
Impairment n (%) 8 (16) 1 (2) 0.014
Patients Controls
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Post-hoc and subgroup analyses
Patients with subjective memory problems scored worse  on Stroop 4 than those without 
subjective memory problems (mean 88.5 seconds (SD=35.4) vs. 68,3 seconds (SD=21.2), P=
0.023), and patients who reported non-complete recovery scored worse than patients who 
reported complete recovery on TMT 5 (mean 20.1 seconds (SD=6.4) vs. 27.5 (SD=10.3),
P=0.014). We found no correlation between NP test results in LNB patients and HRQoL (PCS 
and MCS scores) fatigue (FSS score), depression (MADRS score and previously experienced 
psychological distress), reported malaise, reported concentration problems or persisting 
neurological findings 30 months after treatment.
Overall nine patients had NP impairment as assessed by the global NP sumscore and 14 
patients had remaining objective neurological findings 30 months after treated LNB. Five 
patients had both NP impairment and remaining neurological findings, thus in total 18 (36%) 
of the patients had objective findings regarding NP impairment and/or neurological deficits 
after treated LNB.
Paper III: Risk factors for a non-favorable outcome after treated European 
Neuroborreliosis.
The results of the univariate analyses are presented in Table 20 and 21
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Table 20. Associations between demographic and clinical variables and Health Related 
Quality of Life and fatigue 30 months after treated Lyme neuroborreliosis
*The difference is between the group with 4-6 years education and the group with more than 7 years of 
education after primary school. SD; Standard deviation, CI; Confidence interval, PCS; Physical Composite 
Summary and MCS; Mental Component Summary of the Health Related Quality of Life questionnaire SF-36 
(Short Form-36), FSS; Fatigue Severity Scale
PCS MCS FSS 
Variable (n) Mean (SD) P-value Mean (SD) P-value Mean (SD) P-value
Gender   Male (27)
Female (21)
45.2 (11.1)
44.2 (8.2)
0.738 50.9 (11.5)
48.6 (11.9)
0.501 3.5 (2.0)
3.5 (2.0)
0.950
Education: years after primary school*
0-3 (24)
4-6 (16)
>7 (10)
44.1 (7.9)
41.2 (12.1)
51.6 (7.4)
0.030 48.7 (14.2)
52.3 (9.6)
49.0 (7.7)
0.646 3.7(2.0)
3.5 (2.4)
3.0 (1.3)
0.667
Comorbidity pre-treatment 
Yes: (20)
No: (30)
39.9 (10.1)
47.9 (8.5)
0.005 48.5 (13.6)
50.8 (10.3)
0.576 4.4 (1.9)
2.9 (1.8)
0.009
Treatment 
Ceftriaxone (26)
Doxycycline (24)
45.4 (10.9)
44.1 (9.0)
0,642 47.7 (12.6)
52.1 (10.3)
0.186 3.9 (1.9)
3.1 (2.1)
0.226
Diagnostic accuracy 
Definite LNB (34)
Possible LNB (16)
45.5 (8.8)
43.3 (12.0)
0.471 49.0 (12.0)
51.8 (11.0)
0.426 3.4 (2.0)
3.7 (1.9)
0.627
Pre-treatment CNS manifestations
              Yes: (4)
No: (46)
42.8 (4.8)
44.9 (10.2)
0.731 50.1 (18.3)
49.9 (11.4)
0.973 3.4 (2.5)
3.5 (2.0)
0.920
Pre-treatment duration  6 weeks
Yes: (10)
No: (38)
34.6 (8.5)
47.4 (8.5)
<0.001 48.1 (13.2)
50.4 (11.3)
0.590 5.4 (1.9)
3.0 (1.7)
<0.001
Recovery 4 months 
Yes: (18)
No: ( 32)
49.9 (6.4)
41.9(10.4)
0.006 55.6 (4.7)
46.8 (13.1)
0.001 2.1 (1.9)
4.2 (1.2)
<0.001
Recovery 12 months
Yes:  (29)
No: ( 21)
48.6 (9.1)
39.8 (8.7)
0.002 51.7 (8.3)
47.6 (14.9)
0.233 2.5 (1.6)
4.9 (1.6)
<0.001
Continuous variables, correlation: Pearson’s 
correlation 
coefficient 
[95% CI]
P-value Pearson’s 
correlation 
coefficient 
[95% CI]
P-value Pearson’s 
correlation 
coefficient 
[95% CI]
P-value
Age, years , mean=56(SD=13) -0.165      
[-0.429-
0.124]
0,262 0.029 [-
0.257-0.31]
0.847 0.148       
[-0.135-
0.409]
0.305
Clinical score pre treatment mean, 
weeks mean 8,3(SD=4.3)
-0.251       
[-0.499-
0.035]
0.086 -0.243        
[-0.493-
0.044]
0.096 0.449 
[0.196-
0.646]
0.001
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Table 21. Associations between laboratory findings and Health Related Quality of Life and 
fatigue after treated Lyme Neuroborreliosis
SD;  Standard deviation, CI; Confidence interval, PCS;  Physical Composite Summary and MCS; Mental 
Component Summary of the Health Related Quality of Life questionnaire SF-36 (Short Form-36), FSS ; Fatigue 
Severity Scale, BAB; Borrelia Antibodies, OCB;  Oligoclonal Bands, CNS; Central Nervous System, CSF; 
Cerebrospinal Fluid. 
PCS MCS FSS 
Categorical variables (n) Mean (SD) P-value Mean (SD) P-value Mean (SD) P-value
Intrathecal BAB  production 30 months
Yes:(17)
No: (11)
44.1(10.1)
43.3 (11.8)
0.875 51.9 (9.1)
45.3 (16.5)
0.195 3.4 (2.1)
3.6 (2.1)
0.788
CSF OCBs pre-treatment 
Yes: (24)                                        
No:(13)
45.9 (8.9)
43.9 (7.4)
0.498 52.4 (9.3)
46.4 (13.5)
0.127 3.3 (1.7)
3.5 (2.3)
0.725
CSF OCBs30 months  
Yes: (12)
No:(16)
44.1(9.4)
43.5 (11.8)
0.888 44.7 (10.7)
52.8 (14.1)
0.101 4.0 (2.1)
3.9 (2.1)
0.906
Continuous variables, correlation: Pearson’s 
correlation 
coefficient 
[95% CI]
P-value Pearson’s 
correlation 
coefficient 
[95% CI]
P-value Pearson’s 
correlation 
coefficient 
[95% CI]
P-value
CSF cell count pre-treatment
(cells/mm3)  n=50 mean 187 (SD=255)
-0.079 [-
0.355-
0.209]
0.594 -0.088 [-
0.363-0.201]
0.552 0.158 [-
0.125-
0.417]
0.273
CSF cell count 4 months (cells/mm3)
n=50 mean 7.8 ( SD=11.4)
-0.031 [-
0.339-
0.283]
0.852 0.017 [-
0.296-0.326]
0.981 0.046 [-
0.261-
0.345]
0.771
CSF cell count 12 months (cells/mm3)
n=29 mean 3.72 (SD=12.1)
0.011 [-
0.363-
0.382]
0.955 -0.333 [-
0.628-0.045]
0.084 0.144 [-
0.234-
0.484]
0.458
CSF protein level pre-treatment (g/l )
mean 1.22 (SD=0.73)
0.088 [-
0.201-
0.363]
0.551 0.114 [-
0.175-0.385]
0.441 -0.020 [-
0.296-
0.259]
0.891
CSF protein level 4 months (g/l) (n=42)
mean 0.61 (SD=0.24)
-0.017 [-
0.326-
0.296]
0.095 -0.086 [-
0.387-0.231]
0.600 0.263 [-
0.044-
0.524]
0.093
CSF protein level 30 months (g/l) (n=29)
mean 0.51 (SD=0.20)
0.064 [-
0.316-
0.426]
0.747 -0.237 [-
0.56-0.149]
0.224 0.134  [-
0.244-
0.477]
0.488
CSF CXCL 13 level pre-treatment
(n=32) mean 5227(SD=11915)
-0.194 [-
0.513-
0.172]
0.296 -0.002[-
0.356-0.352]
0.990 0.232 [-
0.126-
0.537]
0.202
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Demographical and clinical variables
We found that pre-treatment symptom duration >6 weeks (B=-10.2, 95% CI -18.8- -6.7, 
P=0.002) and non-complete recovery at 1PRQWKVFOLQLFDORXWFRPHVFRUH% -5.6, 95% 
CI -10.8- -0.5, P=0.033) were associated with a worse PCS mean score. The final model 
explains 59% of the outcome variation (R2=0.59). Non-complete recovery at 4 months (B=-
8.9, 95% CI -15.5- -2.2, P=0.01) was associated with a worse MCS mean score. The final 
model explains 37% of the outcome variation (R2 = 0.37). Pre-treatment symptom duration >6
weeks (B=1.3, 95% CI 0.15-2.4, P=0.028), a higher clinical score pre-treatment (B=0.1, 95% 
CI 0.002-0.2, P=0.019) and non-complete recovery at 12 months (B=1.7, 95% CI 0.7-2.6, 
P=0.001) were associated with a higher burden of fatigue. The final model explains 70% of 
the outcome variation (R2=0.70). Our hypothesis that some of the demographical and clinical 
variables could predict outcome was met. Gender, comorbidity, treatment option, diagnostic 
accuracy, educational level and signs of infectious involvement pre-treatment of the CNS did 
not predict the outcome after treated LNB in our cohort.
CSF variables
Because of missing data at 4, 12 and 30 months, we analyzed the CSF findings separately.  
None of the CSF variables reached a significance level of P 0.05 in the univariate analyses 
or in the regression model, so neither cell count, protein level, anti-Bb antibodies, presence of 
oligoclonal bands, nor CXCL-13 at baseline or during follow up predicted outcome regarding 
fatigue and HRQoL in this cohort.
We did not find evidences of active Bb infection at 30 months follow-up after treatment in 
any of the patients. One patient had significant pleocytosis at 30 months follow-up, but this 
patient had a re-infection with Bb with new emerging symptoms that resolved after treatment 
with intravenous ceftriaxone. Eight patients (28%) had slightly elevated CSF protein level, 17 
(61%) had intrathecal anti-Bb antibody production, and 12 (43%) had presence of CSF 
oligoclonal bands 30 months after treatment. CSF CXCL-13 was measured in 32 (64%) of the 
patients pre-treatment and in 10 (20%) of the patients at 30 months follow-up. Out of these 32
(72 %) had an elevated CSF CXCL-13 levels before treatment, and none 30 months after 
treatment.
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Post hoc analyses
Non-complete recovery at 30 months (composite clinical score >1) was correlated to the mean 
score on PCS (Pearson’s correlation coefficient -0.474 95% CI- 0.668- -0.22 P= 0.001), MCS 
(Pearson’s correlation coefficient -0.369 95% CI -0.591- -0.095, P=0.010) and FSS (Pearson’s 
correlation coefficient 0.556 95% CI 0.329-0.722 P<0.001).
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5. Discussion
5.1 Methodological aspects
Diagnostic accuracy of LNB cases 
There is no gold standard for the diagnosis of LNB. Direct detection of Bb in blood and CSF 
is difficult, as the number of bacteria in these fluids is low, and culturing requires special 
conditions that can be hard to achieve. Clinicians and researchers therefore have to rely on a 
combination of clinical findings, patient history and laboratory results to diagnose LNB. The 
LNB patients in our cohort were selected according to strict diagnostic criteria meeting those 
from the European Foundation of Neurological Societies (EFNS) published in 2010 for 
definite and possible LNB [25].  To reflect everyday clinical praxis, and to avoid treatment 
delay, the patients were included in the treatment trial before the results of intrathecal anti-Bb
antibody production were available. This is one of the reasons why one third of the patients 
were classified as having possible LNB, without anti-Bb antibody production. The patients 
with possible LNB (n=16) had other laboratory findings supporting the diagnosis, like CSF 
pleocytosis which normalized after treatment, high CSF CXCL-13 levels before treatment, 
and three patients developed intrathecal anti-Bb antibody production after some weeks. In 
addition, those with a possible LNB had typical clinical presentations; 14 (88% had a 
complete or partial Bannwart syndrome with radiculitis, palsy of cranial nerves, and/or 
pareses in the extremities. Two (12%) of the patients with possible LNB had only subjective 
symptoms pre-treatment (myalgias, asthenia, pain, malaise), they both had pleocytosis that 
normalized after treatment). For pre-treatment clinical and laboratory characteristics of the 
patients see Table 10 in the method part of this thesis. In summary we aimed for a high 
diagnostic accuracy of LNB cases to limit the possibility of including patients with other 
infectious diseases or disabilities with overlapping symptoms, and think we achieved this.
Control group 
We followed a cohort of LNB patients prospectively, but the main outcomes in the present 
study (HRQoL, FSS, and NP functioning) were assessed only once, namely at the 30 month 
follow-up visit. A cross-sectional design like this gives information of the prevalence of our 
findings and associations between our observations, but does not allow any causative 
conclusions. Without comparable baseline scores of HRQoL, FSS or NP functioning, we 
don’t know if our 30 month follow-up scores mainly reflect symptoms and signs that 
characterized the patients before they got LNB.  To be able to relate our findings to LNB, we 
included a control group as similar as possible to our patient group, but without a history of 
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LNB. We recruited controls from the same geographical area as the patients, and because we 
wanted to assess variables that could be influenced by socioeconomically status and age, we 
matched the two groups for gender, age and educational level. The perfect control group is in 
practice almost impossible to obtain. HRQoL, fatigue and NP assessments might be 
influenced by several coexisting diseases or disorders found in the general population. The 
optimal control group should have the same frequency of coexisting diseases, and identical 
problems regarding pain, abilities and intelligence. We asked the patients to bring their own 
controls in order to improve the matching, especially regarding education. Of course the 
chance of getting more healthy controls is present (because it is easier to ask a healthy family 
member to come), and differences in outcome found between the two groups could be over-
estimated. 
On the other hand, we did not exclude controls with diseases or conditions that could 
influence the outcomes, like chronic diseases or a history of depression. The only exclusion 
criterion for the controls was a history of LNB. We did not test the control group for anti-Bb
antibodies out of two reasons: Firstly, we know that the background seropositivity in our 
region is around 15-20% [14]. Secondly, we think that the reports from the patients about 
earlier LNB are reliable enough, as symptoms of LNB are normally easily recognized. 
Furthermore, the physicians in our region are familiar with the disease and ignored 
symptomatic LNB is probably a rare phenomenon. 
The rate of diseases except LNB was comparable between patients and controls, so we think 
that the differences we found in outcome scores are not biased by more or less morbidity in 
the control group as compared to the patient group.
More controls than patients were retired from work, but mean age and educational level was 
similar in the two groups and we do not think that this affects our results either. 
Overall, we believe that our control group is valid for our purpose, but we realize the 
limitations.
Main outcomes
The patient’s point of view on how a disease affects their well-being and everyday 
functioning is essential. Our clinical experience was that many patients with LNB complained 
of symptoms like reduced Qality of Life, fatigue and neurocognitive impairments, in spite of correct 
treatment, and we therefore chose main outcomes in our study that measured these aspects. 
We have used well established evaluation instruments described in the method chapter.
Even though the assessment of quality of life has gained more or less general acceptance as a 
measurable entity, it is optimistic to believe that all the dimensions of a patient’s life can be 
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covered by a 36- item scheme like the SF-36. The HRQoL varies in different situations and at 
different times, and the individual’s opinion of the importance regarding different aspects of 
HRQoL also varies. It is important to know if the issues we are measuring is important to the 
patient and have an impact on his or hers everyday life.  Many questionnaires, including SF-
36 consider these aspects and includes questions like what issue the person questioned finds 
the most important, and in which degree he or she thinks this affects his or her daily life. In 
this way we can assume  that if a person scores poorly on the HRQoL questionnaire it does, in 
the patients opinion, affect his or her life. 
The word “fatigue” is translated into “utmattelse” in Norwegian, a term that in my opinion 
seems to be understandable to most of the patients and distinguishable to “tired” (in 
Norwegian: “trett”) and “worn-out” (“utslitt”). To assess fatigue we used the fatigue severity 
scale (FSS) which is a reliable, validated scale, and measures the impact of physical fatigue 
on daily life.  Furthermore, FSS is a generic scale which gives us the opportunity to compare 
our results to the scores in the general population, and to FSS scores in studies of other 
diseases. FSS was developed to assess Multiple Sclerosis associated fatigue, and prior studies 
have shown acceptable internal consistency and stability over time, and also good sensitivity 
to changes caused by clinical improvement [132]. A more detailed description of the FSS is 
found in the method section of this thesis.
We based the selection of NP tests upon those used in relevant studies of cognition in LD, 
which had revealed significant differences between patients and control groups. We also 
wanted the test battery to cover a broad spectrum of neurocognitive domains, and if possible, 
use tests validated in Norway. Previous studies had reported deficits in memory, 
attention/executive functions, and in processing speed in LNB patients. The TMT test, the 
Digit symbol test and the Stroop tests attends to be good choices; as they were standardized, 
tried out in Norwegians, and they are commonly applied as part of NP assessments.  
The CVLT assesses episodic verbal memory, and is commonly used, also in LD studies. 
Westervelt et al. concluded in their review that a memory test based on learning and recall of 
a word list seems to be more sensitive to detect memory deficits after LD than other 
techniques (like remembering a story) [100]. Several LD studies including the CVLT have 
found significant verbal memory problems in LD patients compared to controls, but the 
CVLT subtest performance profile vary.
The Digit symbol test primarily assesses processing speed, but it also tests visual memory and 
incidental learning. Several studies have found deficits after LD in verbal fluency, but tests 
assessing this function were not included in our study. Verbal fluency is a vulnerable function 
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connected with executive functions, and might have been important to assess. We have 
assessed executive functions with tests like Stroop 1-4 and TMT 1-4. 
NP tests in general have a high sensitivity and are useful to detect even small NP deficits, but 
they have a low specificity. It can be challenging to decide which defined cognitive deficit is 
causing the problems, e.g. is it a memory problem or maybe an attention problem, or a 
combination of both? 
A weakness of our study is that we did not assess IQ. However, several of the American 
studies included an IQ assessment or an estimation of IQ, and did not find IQ to be affected 
after LD [101]. To minimize this problem in the present study we matched the control group 
and the patients regarding age, educational level, and geographical region, known to correlate 
in some degree with intelligence [133]. The fact that the patients chose their controls in their 
own surroundings will also make the groups more comparable regarding IQ. 
For the clinical status, during and after LNB, we used a composite clinical score based on a
standardized interview and a clinical neurological examination. We regard this clinical score 
as a less sensitive and specific indicator of long-term outcome than HRQoL, FSS and NP test 
scores, and more susceptible to confounding. Consequently we chose not to use it as a main 
outcome measurement, rather as a measurement of clinical status throughout the study.
Potential biases
Selection of patients
We did not include all patient (n=112) from the treatment trial in this follow-up study. Out of 
economical and logistic considerations we had to include only a subgroup. Sixty-four of the 
112 patients participating in the treatment trial were living in the geographical region of 
Agder counties, and we decided to include those of these 64 who were treated between May 
2004 and December 2007, namely 57 patients. Fifty of these patients consented to participate 
and were included. To minimize the chance for selection bias, we compared our 50 included 
patients to the whole patient group from the treatment trial, and to the seven who were invited 
but declined to participate, and found no differences regarding illness severity before or after 
treatment, or regarding treatment options. Therefore, we think that our subgroup is 
representative for the whole cohort.
Mean pre-treatment symptom duration was 9.2 weeks in the whole cohort, and one interesting 
question is if a subgroup of patients with longer standing symptoms could have influenced our 
results. Ten patients had pre-treatment symptom duration more than 6 weeks, including four 
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patients with symptom duration more than 6 months. We do not think that our results are 
skewed by a these patients as the outcome regarding PCS, MCS, FSS and the NP tests did not 
differ between patients with and without pre-treatment symptom for more than 6 months. 
Co-morbidity
Infections with other pathogens can also cause symptoms similar to those seen in LNB. 
Patients without anti-Bb antibodies were tested for Herpes simplex, Varicella zoster and 
entero-virus using CSF PCR with a negative result, and all patients were tested for anti-TBE
antibodies, three patients were IgG positive and none were IgM positive for anti-TBE
antibodies. Some researchers have discussed if a co-infection with Anaplasma, could give rise 
to a more serious disease. We did not test for Anaplasma, but symptomatic Anaplasma 
infections in humans are rare in Norway, and only two cases are documented.  Serological 
analyses of blood samples of anti-Bb antibody positive patients in Norway, however, have 
shown that 10% are positive for both Bb and Anaplasma [118;134]. We still think that the 
chance of ignored cases of Anaplasma infections that might have altered our results is very 
little as such infections usually cause typical changes in the platelet and leukocyte count, and 
such changes were not present in our patients.
We asked all our patients and controls about somatic and psychological comorbidity. The 
mean age in the groups was 56 years, and of course some had other chronic diseases including 
psychological distress in their past history which could potentially alter the results of HRQoL,
fatigue and NP assessments. We have, however, shown that our two groups are comparable 
regarding amount and severity of comorbidity, and we do not think that the differences found 
between LNB treated patients and controls in our study are confounded by coexisting
diseases. Episodes of psychological distress during lifetime is quite common in the general 
population, and to be able to identify those who had  a more serious psychiatric disease we
asked about any psychiatric disease or psychological distress in the past or present which led 
to medical or therapeutic treatment or sick leave. Ten (20%) patients vs. 8 (16%) controls 
answered yes to this question, P=0.595), which is comparable to the prevalence in the general 
population in Norway [135].
Missing data
Missing data is a problem when dealing with epidemiological studies, and to be prepared for 
this we invited 14 patients more than the 36 required according to sample size calculations 
before study start. In contrast to the clinical and questionnaire obtained data which were 
almost complete, some laboratory data were missing. It was too demanding for some patients 
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to do all the planned spinal taps, and this resulted in a decreasing number of CSF samples 
available for analyses. In addition, by accident in our laboratory 19 CSF samples were 
destroyed before the final analyses of CSF CXCL-13 had been done. As a result of this, only 
10 CSF samples were available for CSF CXCL-13 analyses. It is important to keep the 
missing CSF samples in mind when analyzing the laboratory data, and when considering the 
study results. In the risk factor study (paper III) we analyzed the laboratory data separately 
because of this. 
Regarding the HRQoL SF-36 scores, two patients and one control missed a few items on the 
questionnaire, but in 48 patients we could calculate the sum scores MCS and PCS, so we did 
not impute missing data. 
On the NP tests four patients had missing data on in average 2.5 of  the 23 tests, and four 
controls missed in average 1.5 of the 23 subtasks, therefore we decided to impute the missing 
data to be able to include all patients and controls in the NP outcome analyses. 
Under- and over-reporting of complaints
Self-rating questionnaires and NP assessments might give rise to information biases, as the 
tests can be administrated differently by different investigators. To minimize this problem we 
let one neurologist (the main investigator), trained as suggested by the NP foundation by an 
experienced neuropsychologist, do all the testing in patients and controls. The investigator 
was available for questions during the completion of the self-rating questionnaires to clarify 
misunderstandings, and tried to inform the participants as correctly, encouragingly and 
uniformly as possible. We also tried to keep the surroundings as comparable as possible from 
one participant to the other, including the time of the day, and interruptions and disturbing 
sounds from outside the room was avoided as far as possible. 
At follow-up the patients` mean age was 55 years, and quite a lot of them were of an age 
where it is natural to start thinking about retirement from work. One can speculate if some of 
the five patients that reported that they retired from work because of problems after LNB 
(aged 61, 63, 63, 65 and 66 years at the time of treatment) would have become retirees 
anyway? It may be reasonable to think that the remaining complaints after LNB sort of          ” 
pushed them over the edge”. 
The fear of non-complete recovery and remaining complaints after a severe infection affecting
the nervous system can bring people to over-report symptoms. Stories of dramatic 
consequences after LNB in the daily news do not make this less expectable
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It can be difficult for a person to remember details of the disease history months to years later. 
Most of the demographical and many clinical variables from the early phases of the disease 
were available to us in the research database, and we also checked the patient’s histories with 
the hospital records. In this way we think that the chance of recall biases was limited.
Internal validity
As our main outcome we used the validated and reliable version 2 of the SF-36 test. This is 
much used all over the world, and internal consistency and test-retest studies have been
conducted. In Norway Loge and Kaasa reported reliability estimates in 1998, and Cronbachs 
alpha varied from 0.80 to 0.93 on the 8 subscales, which is very high [127]. The FSS showed 
satisfactory internal consistency (Cronbachs alpha 0.88) in a study of the Norwegian version 
[76].
The 2.version of the CVLT was translated into Norwegian in 2004, and in 2007 it was 
validated in 128 Norwegian patients who had previously been tested with CVLT version  The  
conclusion was  that CVLT 2 was found satisfactory and applicable in Norwegian patient 
populations. A validation in a larger population of healthy Norwegians is warranted, though 
[97]. The color-word interference test (modified Stroop test) has satisfactory reliability [99]
and was translated to Norwegian in 2005 as part of the D-KEFS (Delis- Kaplan Executive 
Function System). Digit symbol is a part of the WAIS-III (Wechsler Adult Intelligence Scale-
III) test battery. It has been translated into Norwegian- but uses American norms. The Digit 
symbol is reliable and valid and commonly used around world [136]. TMT is also a part of 
the D-KEFS,  test reliability varies considerably depending on what kind of difficulties the 
test person has (e.g. motor problem in arm may interfere with test results) In the TMT version
used in D-KEFS, as we used, TMT 5 is added to compensate for the fine motor component. 
Spreen and Straus have made a list of studies done on reliability of TMT without the 
compensating TMT 5, and most of them had a Cronbachs alpha over 0.60, many over 0.90
[99].
The calculating of a general NP score that combined all the 23 sub tasks can be criticized. The 
tests and subtasks assess different aspects of cognition and to put them together in one global 
outcome variable as if they were assessing one function may seem odd. However, previous 
studies have not revealed a typical NP deficit profile in treated LNB patients, and this method 
of counting the number of “failed” tests in a battery of NP tests (in the present study defined 
as minus one standard deviation from the mean of the control group) to form a global 
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cognitive function, is not uncommon, also in LD studies [90;101]. We therefore chose such an 
approach to get an impression of the severity of the neurocognitive overall symptom burden, 
and think this can be justified.
It can be problematic that the main investigator of the study did the testing. This can of course 
lead to false positive results in the direction of more substantial findings towards a “wanted” 
outcome. However, the neuropsychologist that scored the tests was blinded to group 
adherence. A great advantage of one person doing all the testing is the avoidance of inter-rater 
biases which can be substantial regarding NP testing.
Multiple tests
In our study we compared a lot of variables to several outcomes. The PCS and the MCS are 
sumscores of eight sub-dimensions of HRQoL, and these subscales are again summarized 
from 36 questions, each with several answer options. The NP assessments consist of four tests 
with 23 subtasks. It is important to realize that the chance of false positive and false negative 
differences is present. The probability of correlating variables that are dependent on each 
other and cover parts of the same qualities is obvious. We did not do a Bonferroni correction 
when analyzing the many scores of the SF-36 and the NP tests, and this should be brought 
into discussion when looking at the results. We think it is important to present our results 
without such a correction as this procedure would have been too conservative and 
inappropriate for our data, and many real differences could have been missed (type two error)
[137]. The relatively big sample size, the inclusion of a control group, and the trend that the 
patient scored significantly lower as compared to controls in almost all the sub-dimension of 
the SF-36 (except pain) showed a difference in the two groups, strengthen our conclusions. 
Further the trend was that patients scored lower than controls in all NP sub-tasks except two.
In the risk factor study (paper III) we chose to do a multiple regression. With this method we 
could analyze several presumably correlated variables in the same model. The significant 
associations between the outcome measures PCS, MCS and FSS and demographic, clinical 
and laboratory data found in the univariate analyses which were excluded in the multiple 
regression analyses were probably confounders. The outcome variation was better predicted 
by those variables which were included in the multiple regression models
External validity
We have tried to design our study, and choose our cohort as close up to everyday clinic as 
possible to be able to generalize the results. We have included patients with possible and 
definite LNB diagnosis, and patients with long and short pre-treatment duration of symptoms. 
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Moreover, we did not exclude patients with other somatic or psychiatric diseases that might 
affect cognitive function, fatigue burden or Quality of Life, and our group of patients is not 
restricted to those with persisting complaints after treatment of LNB. We have not included 
children; they normally have a better long term prognosis than adults.  
5.2 Discussion of the results
We have compared our results to other previous conducted studies on treated LD, and we find 
that our study adds important information about long term outcome after treated LNB 
regarding HRQoL, neurocognition and fatigue. Few controlled studies are addressing these 
matters in Europe, which makes this study important.
HRQoL
We found that LNB treated patients had reduced HRQoL compared to controls as assessed 
with the SF-36 summary components PCS and MCS (PCS, 44 (SD=9) vs. 51 (SD=6) P<0.001 
and MCS, 49 (SD=11) vs. 54 (SD=6), P=0.010) 30 months after treatment. The patients 
scored lower on all the eight sub-dimensions of the SF-36, except for bodily pain. LNB 
patients who reported complete recovery (56%) had similar HRQoL scores as the controls
(paper I). Delayed start of treatment and remaining complaints at 4 and 12 months after 
treatment seem to predict a worse outcome with respect to HRQoL. Age, gender, educational 
level, diagnostic accuracy, treatment option, signs of infectious involvement of the central 
nervous system or coexisting somatic or psychological distress were not associated with 
HRQoL outcome 30 months after treatment in our cohort,  neither were any of the assessed 
CSF findings before treatment or during follow-up (paper III).
Our findings of reduced HRQoL months and years after treated LNB are supported by some
previous studies done in the US, but the patients’ scoring profile differed some from our 
findings. Shadikc et al. did a small study of LD patients 6 years after treatment in 1994, and 
found a reduced global health status [61]. They did a larger study 6 years later, and found 
lower scores in all the eight SF-36 dimensions in LD treated patients as compared to healthy 
controls in the univariate analyses, but the only dimension surviving the multiple regression 
analysis was bodily pain.  Interestingly, pain was the only dimension that did not differ 
between patients and controls in our study group. In addition to assessing pain as one of eight 
dimensions in SF-36, we also asked about pain in the semi-quantitative interview, and there 
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was no difference in the proportion of persons reporting pain among patients and among 
controls. The reason may be that Bb afzelii and Bb garinii, which are the dominating Bb
species in our region, have less affinity to joints and muscles than Bb sensu stricto, which 
dominate in the US. The Bannwarth syndrome with radiculitis is indeed very painful, but the 
pain is often relieved in a couple of days after initiating antibiotic treatment, and vanishes 
after the treatment. Another possible explanation can be that cognitive deficits and fatigue
overwhelmed pain. 
Kalish et al. conducted a study in randomly selected patients from the original study from
Lyme. They compared HRQoL, using SF-36, in healthy controls to three groups of patients; 
patients with LNB, patients with LD without affection of the nervous system (mainly EM), 
and patients with LD arthritis. They found that patients with involvement of the nervous 
system during the acute phase of the disease (facial palsy) that did not receive antibiotic 
treatment had more physical limitations (PCS) and bodily pain 20 years after disease than 
those who received antibiotic treatment. The antibiotic treated LNB patients had similar 
HRQoL scores as healthy controls. In contrast to this, we found physical limitation (low PCS 
scores) in our patients as compared to controls despite adequate antibiotic treatment [41].
In 2000 Seltzer et al. compared HRQoL in LD patients (not restricted to LNB) and healthy 
controls, and found no differences in SF-36 scores. Very few of the patients had signs of 
nervous system involvement (in more than 80 % EM was the main clinical manifestation), 
and lumbar puncture was not done. This study confirms that patients with EM have an 
excellent outcome after treatment, and the results cannot be directly compared to ours, as we 
only included patients with LNB [65].
SF-36 is also used as outcome measure in effect evaluation of prolonged antibiotic treatment 
in patients with remaining complaints after LNB. The treatment trial by Klempner et al. from 
2001 reported an improvement of the HRQoL after 10 weeks with intravenous ceftriaxone, 
but the adverse events were substantial, and the treatment was not recommended [64].
We believe that none of the earlier studies of long term HRQoL in LD are directly 
comparable to our study, mainly because of the various inclusion criteria and study designs, 
and not least because they all are conducted in the US. After our study was published, a 
European research group applied the SF-36 questionnaire on German patients suspected to 
have “chronic Lyme “despite treatment [24]. They compared four groups of “chronic LD” 
patients to healthy controls, one seronegative group without any evidence of a Bb infection,
one group of seropositive patients with other diseases that explained their complaints, one 
group of seropositive patients without other diseases that explained their complaints, and one 
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group with a proven history of LNB (PLDS patients). All three analyzed groups had reduced 
HRQoL and more depressive symptoms than the healthy controls, but as far as we can 
ascertain, the results of the HRQoL assessments in the six PLDS patients are not yet 
published.
Why some patients have reduced HRQoL after adequately treated LNB is much debated. It 
seems logical that the fear of serious problems after an infectious disease in the nervous 
system might reduce the chance of recovery and cause reduced HRQoL. When we planned 
the study, this was one of our main theories, and we decided to assess depression by the 
MADRS questionnaire and by interviewing the patients and controls about their psychological
distress and psychiatric history. Others have reported association between psychiatric 
comorbidity and complaints after LNB [123]. Interestingly, our study results did not support 
the hypothesis that the patients’ complaints are based on depressive symptoms. Despite a 
difference between the groups in mean MADRS scores, the mean scores were below cut-off 
for depression in both groups and only one patient had a MADRS score indicating depression 
in need of therapy (21), and one patient (16) and one control (10) had a slightly elevated 
MADRS score. The MADRS scores also did not differ between patients reporting recovery 
and patients reporting non-complete recovery at 30 months follow up, and the patients and 
controls had comparable histories regarding psychiatric and somatic comorbidity. Our 
findings are supported by a study by Hajek et al [122], but not by the study by Solomon et al. 
which found that psychiatric impairment before LNB resulted in more chronic symptoms 
afterwards [121].
Apathy is found in many neurological diseases, and is known to reduce HRQoL in 
Parkinson’s disease [138]. We found a difference between mean scores in SAS between LNP
patients and controls, but do not regard the measured difference to be of any clinical 
importance due to scores below cut-off for apathy in both groups. Further, we found 
comparable proportions of persons with high SAS (> 14) scores in the two groups.
Fourteen patients (28%) had objective neurological findings at 30 months follow-up. The 
neurological deficits were mild, but these 14 patients scored lower on PCS and on FSS, as 
compared to the rest, so the neurological deficits seem to have a functional impact.  This is 
also reported in other Scandinavian studies, Berglund reported 12% and Hansen reported 5%
of patients with disabling neurological deficits after treatment [28;53].
In conclusion our results demonstrate that European LNB patients have poorer HRQoL 30
months after treatment than matched controls. The underlying pathogenesis is unknown, but 
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pre-treatment symptom duration >6 weeks and non-complete clinical recovery during the first 
year after treatment seem to be risk factors for a non-favorable outcome regarding self-
reported HRQoL.
Fatigue
The patients scored lower than controls on the FSS (mean FSS scores 3.5 vs. 2.1 P<0.001),
and 50% of the patients and 16% of the controls (P=0.001) answered that fatigue was an 
everyday problem to them.  The proportion of persons suffering from fatigue differed between 
patients and controls both when using four and five as cut-off YVVFRUHGRQ
the FSS, PDQGYVVFRUHGRQWKH)66 P=0.001). Delayed start of 
treatment, a more severe disease before treatment and non-complete recovery at 4 and 12 
months seem to predict more fatigue 30 months after treatment.
We did not find correlation between NP functioning and fatigue (P= 0.892) as was found in 
previous studies [90;92;94], but the FSS score in the LNB patients was correlated to PCS 
(P=<0.001) and MCS (P=0.001). In other conditions like Parkinson’s disease fatigue is also 
shown to contribute to reduce HRQoL [59].
Although fatigue is a common problem both in the general population and in several acute 
and chronic diseases, we do not know the underlying patophysiology. This is of course 
frustrating, as it also restricts the possibilities of finding good treatment strategies. We found 
that a delayed treatment, more subjective symptoms and objective findings before treatment, 
and non-complete recovery at 12 months predicted more fatigue 30 months after treatment. 
The importance of starting the treatment early is supported by other reports [53;61;101;139].
Our findings are also in accordance with the theory that more severe disease gives rise to a 
less favorable outcome.  Is this due to more serious tissue damage, psychological factors like 
fear of remaining problems, late inflammation, an active infection, disturbances of regulatory 
systems or other factors? 
Fatigue is an important symptom in depression, and the overlapping symptoms might cause 
diagnostic challenges, but we did not find depression in our cohort as assessed with MADRS 
(see discussion of HRQoL).
Fatigue is in one study found to be more common in anti-Bb antibody seropositive persons as 
in anti-Bb antibody seronegative persons [85].  The incidence of chronic fatigue syndrome is 
increasing in Norway, as in many other countries. PLDS and Chronic Fatigue Syndrome are 
both syndromes with unknown patophysiology. Many patients and physicians ask themselves 
82
about the possible role of an active or former Bb infection in patients with chronic fatigue 
syndrome. Regularly patients are referred for a second opinion about a “chronic Lyme” 
condition. Experiences from Lyme referral centers in the US show us that an active Bb
infection based on medical history and CSF findings is rare in patients referred for a second 
opinion because of suspected “chronic Lyme” An interesting recent study in a European 
cohort looked at patients who were referred to a specialist centre for a second opinion of 
suspected “chronic LNB”. Out of 112 referred patients nine had ongoing Bb infections, one 
of them LNB. They did a subgroup analysis of 95 of the remaining patients and found that 
39% had another well defined illness which explained their symptoms (including 13 persons 
with Multiple Sclerosis), and only six patients had PLDS according to the proposed categories 
of Feder et al [24]. A recent study showed distinct CSF proteomes that might help us to 
differentiate Chronic Fatigue Syndrome from PLDS; this is interesting and might give us 
some diagnostic tools in the future [87].
One might ask how important it is to identify PLDS in patients with fatigue when we don’t 
have a specific cure to offer them.  I think that the patients will be more susceptible to other 
therapeutic approaches if they know as much as possible about the etiology of their disease. 
This is also supported by a study by Sigal et al., which suggests that the patients with a 
diagnosis of “unexplained syndromes” may be unable to benefit from therapy because of their 
anxiety [86].
Different treatment approaches for fatigue have been tried out, and most of the knowledge 
about this is probably due to research on fatigue in the Multiple Sclerosis population. First of 
all, secondary or additional causes of fatigue, like sleep problems, depression, metabolic 
disturbances, adverse effects of medications and so on must be eliminated. Several studies 
have looked into antibiotic treatment of fatigue after treated LD. Krupp et al. used FSS scores 
as main outcome to evaluate possible treatment effect of ceftriaxone intravenously for 28 days 
in previously treated LNB patients with persisting fatigue (all participants had a FSS of four 
and more before inclusion in the study) [66].  Fallon et al. also used FFS in a treatment trial 
with ceftriaxone for 10 weeks of PLDS patients with objective memory impairments. Both 
studies reported lower FSS scores after treatment. In the first study the treatment was not 
recommended because of side effects, and in the second study, the relief of fatigue found at 
12 weeks, did not persist at 24 weeks [67]. Non-pharmacological treatments of fatigue include 
patient and caregiver education, psychological approaches and physical exercise. Cognitive 
behavioral therapy has shown to be effective in Chronic Fatigue Syndrome, and physical 
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exercise has shown that it may lighten the burden of fatigue in Multiple Sclerosis patients 
[89;140]. This should also be tested in PLDS patients.
In conclusion our results demonstrate that European LNB patients have more fatigue 30
months after treatment than matched controls. The underlying pathogenesis is unknown, but 
pre-treatment symptom duration >6 weeks and a more severe disease before treatment and 
non-complete clinical recovery during the first year after treatment seem to be risk factors for 
a non-favorable outcome regarding self- reported fatigue.
Neuropsychological (NP) functioning
We found that LNB treated patients scored lower on four NP subtasks assessing 
executive/attention functions, processing speed, visual and verbal memory, as compared to 
matched controls (Stroop test 4: 77.6 vs. 67.0, P=0.015, TMT 5: 23.4 vs. 19.2, P=0.004, Digit 
Symbol recall: 6.6 vs. 7.2, P=0.038 CVLT list B: 4.68 vs. 5.50, P=0.003). The distribution of 
global NP sumscores indicates that most of the LNB treated patients perform comparable to 
controls, while a small subgroup have a debilitating long-term course with cognitive 
impairment. Fatigue, depression, neurological deficits or HRQoL at 30 months after treatment 
were not associated with the global NP sum score. The subjective feeling of cognitive 
problems as memory problems or concentration problems does not always correlate with poor 
NP performances [141], but we found that subjective feeling of memory problems correlated 
with lower scores on Stroop 4. The subjective feeling of non-complete recovery correlated 
with poor scores on the TMT 5. 
Westervelt et al. did an excellent review of controlled studies of NP outcome after treated LD 
conducted from 1996 to 2000, and found that the main deficits were related to memory, 
attention/executive function and processing speed [100]. Most studies which have found 
neurocognitive deficits in treated LD patients report memory problems [90-
94;101;102;105;106], and most of the studies report problems with verbal memory and verbal 
learning. McAuliffe et al. found, in a study on adolescents, more visual memory and learning 
problems as we did in our cohort [107]. The LNB treated patients in our cohort had verbal 
memory recall problems when interfered with a distracting wordlist on the CVLT test, and 
visual memory and incidental learning problems on the Digit symbol test. They did not have 
any verbal learning deficits. Several studies have used the CVLT and have reported more 
verbal memory problems than we did: Kaplan et al. found deficits on verbal delayed recall 
and associated verbal learning years after treated LNB [102], Shadick et al. found verbal long 
delay recall in LD patients 6.2 years after treatment [61], Benke et al. found reduced verbal 
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learning, and reduced verbal memory (short time free and cued recall) in LNB patients 
(treated and not treated) years after the infection [101], Ravdin et al. found reduced verbal 
learning and long delay free recall deficits in LD treated patients a year after treatment [92].
We did not find any of these verbal memory deficits, but the patients in our LNB cohort had 
more recall problems when presented with a distraction word list as compared to controls. The 
CVLT test does not assess memory and learning functions alone, attention/ executive abilities 
influence on the verbal learning and memory [95]. The presentation of a second wordlist 
demands organization and attention skills even more, and one possible interpretation is that 
the observed memory problems in our cohort are strongly influenced by attention deficits.
This might be supported by the findings in another test assessing attention/executive 
functions, the Stroop test. Our LNB treated patients scored lower than the controls on the 
most demanding test, Stroop 4, which requires inhibition of response and shifting between 
rules for solving the tasks. Attention/executive function deficits are also found in other studies 
[61;91;101;105].
Processing speed measured by Digit symbol and TMT-5 was lower in LNB patients than 
controls. The TMT-5 task is dependent on motor function in the arm, however, Pollina et al. 
have shown that a poor result in this task is independent of fine motor function and 
proprioception in LD patients, and can be regarded as a more disease specific cognitive deficit 
[94]. Reduced processing speed is also frequently reported in LD treated patients in 
accordance with our findings [61;93;103;105]. Four well designed treatment studies 
[64;66;67;108], have showed no improvement of neurocognitive functions after repeated and 
prolonged antibiotic therapy. 
The main differences between our study and other studies on NP functioning in post-treatment 
LD patients are that we find less verbal memory problems and more visual memory problems. 
The findings of attention/ executive function deficits in our cohort seem to be in accordance 
with several previous conducted studies. We think that the main reasons that our study results 
differ from previously conducted studies are different inclusion criteria and the lack of a 
“disease specific NP profile”. Several of the US studies have only included LNB treated 
patients with persisting complaints [67;90;93;102] while we have included patients with- and 
without persisting complaints. We would expect to find fewer differences in our cohort than 
in a cohort with pre-selected patients with known complaints. On the other hand, patients with 
affection of the nervous system might have more deficits than patients with LD without 
nervous system affection. We found that, a subgroup of LNB treated patients had NP 
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impairments, and that most of the patients performed as good as the control group on NP 
testing. 
Imaging studies have not been conclusive regarding anatomical mapping of structural or 
functional changes of the PLDS [47]. Logigian et al. did a SPECT study in 13 patients with 
Lyme encephalopathy and found hypoperfusion of the subcortical basal ganglia and white 
matter [50]. Fallon et al. examined the regional blood flow and cerebral metabolic rate in 35 
patients with persistent encephalopathy after LD and compared them to healthy controls, and 
found deficits in white and gray matter bilaterally, primarily in the temporal, parietal and 
limbic areas [142].  In another controlled study by Fallon et al. 11 LD treated patients with 
persisting subjective cognitive problems were tested with NP test while Xenon (133)-regional 
blood flow was registered. They found less blood flow changes in white matter especially in 
the posterior temporal and parietal lobes bilaterally. These flow reductions were associated 
with deficits in memory and visuospatial organization assessed by NP testing. They did not 
find any connection between these flow deficits and the small white matter lesions seen in 
some of the subjects [51].
Depression can affect NP function, and some of the previous studies included assessment of 
depression, as did we. Confusingly both negative, positive and non correlation was found! 
Two studies found better memory scores in depressed patients [90;93], others found no 
relationship [91;92;104;143], and some found depression in LNB patients, but not correlated 
to memory scores [105]. Barr found more reported subjectively memory problems in 
depressed patients with serological evidence of late-stage LD in a not controlled study, but all
the 55 depressed LNB patients scored low on the depression rating scales, indicating that they 
were not severely depressed,  and there was no correlation between the performances on 
CVLT and the subjective feeling of memory [141]. Elkins et al. tested 30 post-LNB patients 
but found no association between current depressive symptoms and NP test results. The study 
was limited by the lack of a control group [143].
In summary, these study results indicate that depression is not associated with cognitive 
problems in LNB treated patients. The LNB treated patients in our cohort were not depressed, 
and the cognitive problems found in our cohort cannot be explained by a coexisting 
depression. We think this is an important message to clinicians. 
Only four of our patients had signs suggestive of infection of the CNS before treatment, and 
we found no correlation between CNS affection and global NP sum score functioning (3.6 vs. 
7.3 P= 0.080). This must be interpreted with caution because of the low number of patients
with CNS affection.  
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Fatigue can correlate with NP functioning [90;92;94] but it is uncertain if fatigue is causative 
of the NP test deficits or a confounder.  Studies of fatigue and neurocognitive functioning in 
Multiple Sclerosis has shown that the NP deficits often appear at the end of the test situation 
when the patients have fulfilled many and often more demanding NP tasks [144]. This reflects 
poor vigilance. Our test battery consisted of a limited amount of tests to avoid test related 
fatigue, and we allowed breaks if needed.  We found no correlation between NP test results
and fatigue (self-reported fatigue and FSS score).
Five of our patients blamed persisting complaints after LNB for their retirement of work, but 
this was not associated to the NP scores. 
In conclusion LNB treated patients scored lower on four NP subtasks assessing processing 
speed, visual and verbal memory and executive/attention functions, as compared to matched 
controls. The distribution of NP dysfunctions indicates that most LNB treated patients 
perform comparable to controls, while a small subgroup have a debilitating long-term course 
with cognitive problems.
6. Conclusions 
1. Health Related Quality of Life was reduced in well-defined European patients treated for 
LNB with a current recommended antibiotic regimen 30 months earlier, as compared to 
matched controls. The LNB treated patients were not more depressed and did not report more 
pain than the controls. Fatigue was the most disturbing persisting complaint, and was 
negatively associated with Health Related Quality of Life. Mild neurological deficits were 
found in 28 % of the patients, and seemed to influence negatively on the physical Health 
Related Quality of life and fatigue scores. The patients who reported subjective recovery had 
the same Health Related Quality of Life as the controls.
2. Most of the patients who were treated for European LNB 30 months earlier had comparable 
neuropsychological (NP) functioning to matched controls, but a small subgroup had cognitive impairments
regarding attention/excecutive function, processing speed and memory that could affect their 
daily life. The LNB treated patients with complete recovery had similar NP functioning as the 
controls. We did not find any association between NP test results and Health Related Quality 
of Life or Fatigue.  NP testing should be applied when patients complain of memory 
problems, as these patients have poorer scores in some of the NP sub tasks. A test battery of 
Trail-making test, Stroop test and Symbol digit seems to reveal deficits, and a memory test 
including visual memory is recommended.  
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3. It seems that a more serious LNB disease and a longer duration of symptoms before 
treatment can reduce Health related Quality of Life, and that symptom duration more than 6 
weeks before treatment, a more severe disease and non-recovery at four and 12 months 
predict a higher burden of fatigue 30 months after treatment. We did not find that any 
laboratory data predicted outcome after treated LNB, and there were no Cerebro Spinal Fluid (CSF) findings 
indicating an active Bb infection 30 months after treatment. Gender, age, comorbidity, signs 
of pre-treatment infection of the central nervous system or CSF findings before and during 
follow-up was not associated with Health Related Quality of Life or fatigue at 30 months.
4. Thirty months after treatment of LNB 18 out of 50 patients (36%) had objective findings in 
terms of neurological deficits and/or cognitive impairment.
Clinical implications
LNB should be treated as soon as possible to avoid a non-favorable outcome. Patients should 
be informed that the chances of a favorable outcome after treated LNB are good, but they also 
need to be informed about the possibility of cognitive impairments and fatigue months after 
treatment. If a PLDS is suspected, neurocognitive testing including assessment of memory 
and learning, attention/executive functions and processing speed might be helpful to 
document the condition and to help persons to find coping- strategies.
We probably need a national competence center on tick-borne diseases, situated in a high
endemic region for Lyme disease and Tick-borne Encephalitis. The main responsibilities of 
such a competence center must be clinical research, diagnostic and treatment of persons with 
tick borne diseases, especially the patient in whom the diagnosis is uncertain, in patients with 
more severe disease and patients with a non-favorable outcome. We need practical guidelines 
for the diagnosis and treatment of tick borne diseases based on evidence based medicine, and 
at a national level. 
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7 Future perspectives
Further studies
1. Studies on the pathophysiology of LNB and long term complaints after treatment such as
neurocognitive deficits and fatigue, including imaging studies like functional MRI are 
warranted. Especially the theories about a secondary autoimmune process or cytokine-driven 
immunological damage in the nerve system should be further explored. It is important to do 
studies in Europe as geographical differences on the genotype of the Bb species and 
phenotype of LD exist. Conclusions from US studies cannot be directly transferred to 
European conditions. 
2. Studies that evaluate present and new diagnostic laboratory tests are needed to avoid over 
diagnostic and under diagnostic of LNB. 
3. Our findings of possible risk factors for a non-favorable outcome after treated LNB need to 
be confirmed in a prospective study including a larger study population, especially regarding 
the laboratory findings. 
4.  The neuropsychological impairments found in our cohort may or may not represent a 
specific neuropsychological profile, and should be compared to neuropsychological profiles 
after other infectious or not-infectious diseases that affect the nervous system.  
5. Further studies of treatment options of acute LNB and persistent complaints after treated 
LNB are recommended, both pharmacological and non-pharmacological approaches should 
be explored.
6. Strategies to reduce the fear of a non-favorable outcome after LNB in the public focusing 
on the favorable outcome in most LNB treated persons, and the fact that the diagnosis of LNB 
is commonly unproblematic. 
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